| July 26, 2026 | Peptide | Peptide updated: Gonadorelin | Gonadorelin |
| GnRH for fertility |
| July 26, 2026 | Peptide | Peptide updated: Sermorelin | Sermorelin |
| GHRH for natural GH release |
| July 26, 2026 | Peptide | Peptide updated: Oxytocin | Oxytocin |
| Bonding and relaxation hormone |
| July 26, 2026 | Peptide | Peptide updated: Pramlintide | Pramlintide |
| Amylin analog for diabetes |
| July 17, 2026 | Peptide | Peptide updated: Epitalon | Epitalon |
| Longevity, telomere support |
| July 1, 2026 | Source | New source addeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a… | — |
| July 1, 2026 | Source | New source addeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-9… | — |
| July 1, 2026 | Source | New source addeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b… | — |
| July 1, 2026 | Source | New source addeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e4a41fd-a753-4362-8… | — |
| July 1, 2026 | Source | New source addeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e2c9856-1836-49f0-9… | — |
| July 1, 2026 | Source | New source addeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b… | — |
| July 1, 2026 | Source | New source addeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-8… | — |
| July 1, 2026 | Source | New source addeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a… | — |
| July 1, 2026 | Source | New source addeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-9… | — |
| July 1, 2026 | Source | New source addeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a… | — |
| July 1, 2026 | Source | New source addeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-9… | — |
| July 1, 2026 | Peptide | Peptide updated: Tesamorelin | Tesamorelin |
| GHRH for visceral fat |
| July 1, 2026 | Peptide | Peptide updated: Dulaglutide | Dulaglutide |
| Weekly GLP-1 (Trulicity) |
| July 1, 2026 | Peptide | Peptide updated: Calcitonin | Calcitonin |
| FDA-approved bone resorption inhibitor |
| July 1, 2026 | Peptide | Peptide updated: Abaloparatide | Abaloparatide |
| Advanced bone anabolic |
| July 1, 2026 | Peptide | Peptide updated: Teriparatide | Teriparatide |
| FDA-approved bone builder |
| June 18, 2026 | Peptide | Peptide updated: Insulin | Insulin |
| The foundational peptide hormone for glycemic management in type 1 and type 2 diabetes mellitus. |
| June 18, 2026 | Peptide | Peptide updated: Bivalirudin | Bivalirudin |
| FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients. |
| June 18, 2026 | Peptide | Peptide updated: Exenatide | Exenatide |
| FDA-approved GLP-1 receptor agonist for type 2 diabetes; the first incretin mimetic approved in the US. |
| June 18, 2026 | Peptide | Peptide updated: Desmopressin | Desmopressin |
| Synthetic ADH analog (DDAVP) FDA-approved for diabetes insipidus, nocturnal enuresis, and bleeding disorders |
| June 18, 2026 | Peptide | Peptide updated: Pasireotide | Pasireotide |
| Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly. |
| June 18, 2026 | Peptide | Peptide updated: Lanreotide | Lanreotide |
| FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome |
| June 18, 2026 | Peptide | Peptide updated: Octreotide | Octreotide |
| FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988 |
| June 18, 2026 | Peptide | Peptide updated: GLOW Stack | GLOW Stack |
| Trending injectable research blend of GHK-Cu, BPC-157 and TB-500, marketed for skin rejuvenation and tissue recovery. Not FDA-approved; sold as a research chemical. |
| June 18, 2026 | Peptide | Peptide updated: Bulevirtide | Bulevirtide |
| First/only FDA-approved treatment for chronic hepatitis delta virus (HDV). FDA accelerated approval May 22, 2026. Brand: Hepcludex (Gilead). |
| June 18, 2026 | Peptide | Peptide updated: Pegzilarginase-nbln | Pegzilarginase-nbln |
| PEGylated recombinant arginase enzyme for Arginase 1 Deficiency. FDA approved February 23, 2026. |
| June 18, 2026 | Peptide | Peptide updated: Navepegritide | Navepegritide |
| PEGylated CNP analog for achondroplasia. FDA approved February 27, 2026. |
| June 18, 2026 | Peptide | Peptide updated: Icotrokinra | Icotrokinra |
| Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis. |
| June 18, 2026 | Peptide | Peptide updated: NMN (Nicotinamide Mononucleotide) | NMN (Nicotinamide Mononucleotide) |
| NAD+ direct precursor nucleotide; key longevity compound. |
| June 18, 2026 | Peptide | Peptide updated: Collagen Peptides | Collagen Peptides |
| Structural bone and joint support |
| June 18, 2026 | Peptide | Peptide updated: Calcitonin | Calcitonin |
| FDA-approved bone resorption inhibitor |
| June 18, 2026 | Peptide | Peptide updated: Abaloparatide | Abaloparatide |
| Advanced bone anabolic |
| June 18, 2026 | Peptide | Peptide updated: Teriparatide | Teriparatide |
| FDA-approved bone builder |
| June 18, 2026 | Peptide | Peptide updated: Prostatilen | Prostatilen |
| Prostate and male hormone support |
| June 18, 2026 | Peptide | Peptide updated: Thyreogen | Thyreogen |
| Thyroid function support |
| June 18, 2026 | Peptide | Peptide updated: DHEA Peptide | DHEA Peptide |
| Hormone precursor support |
| June 18, 2026 | Peptide | Peptide updated: Oxytocin | Oxytocin |
| Bonding and relaxation hormone |
| June 18, 2026 | Peptide | Peptide updated: PT-141 | PT-141 |
| Sexual function peptide |
| June 18, 2026 | Peptide | Peptide updated: HCG (Human Chorionic Gonadotropin) | HCG (Human Chorionic Gonadotropin) |
| Testosterone production support |
| June 18, 2026 | Peptide | Peptide updated: Gonadorelin | Gonadorelin |
| GnRH for fertility |
| June 18, 2026 | Peptide | Peptide updated: Kisspeptin | Kisspeptin |
| Reproductive hormone regulator |
| June 18, 2026 | Peptide | Peptide updated: Thymosin Beta-4 | Thymosin Beta-4 |
| Comprehensive tissue pain relief |
| June 18, 2026 | Peptide | Peptide updated: Actovegin | Actovegin |
| Hypoxic pain and healing |
| June 18, 2026 | Peptide | Peptide updated: PEA (Palmitoylethanolamide) | PEA (Palmitoylethanolamide) |
| Natural pain modulator |
| June 18, 2026 | Peptide | Peptide updated: ARA-290 | ARA-290 |
| Neuropathic pain specialist |
| June 18, 2026 | Peptide | Peptide updated: Semax Low Dose | Semax Low Dose |
| Evening cognitive calming |
| June 18, 2026 | Peptide | Peptide updated: Glycine Peptide | Glycine Peptide |
| Sleep quality amino peptide |
| June 18, 2026 | Peptide | Peptide updated: Pinealon | Pinealon |
| Pineal gland bioregulator |
| June 18, 2026 | Peptide | Peptide updated: Melatonin Peptide Complex | Melatonin Peptide Complex |
| Enhanced melatonin delivery |
| June 18, 2026 | Peptide | Peptide updated: Epithalon | Epithalon |
| Circadian rhythm regulator |
| June 18, 2026 | Peptide | Peptide updated: DSIP | DSIP |
| Delta sleep-inducing peptide |
| June 18, 2026 | Peptide | Peptide updated: AMP-K | AMP-K |
| Metabolic immune support |
| June 18, 2026 | Peptide | Peptide updated: KPV | KPV |
| Anti-inflammatory immune peptide |
| June 18, 2026 | Peptide | Peptide updated: Splenopentin | Splenopentin |
| Spleen-derived immune peptide |
| June 18, 2026 | Peptide | Peptide updated: Beta-Glucan Peptide | Beta-Glucan Peptide |
| Immune activating complex |
| June 18, 2026 | Peptide | Peptide updated: Groprinosin | Groprinosin |
| Antiviral immune booster |
| June 18, 2026 | Peptide | Peptide updated: Imunofan | Imunofan |
| Russian immune peptide |
| June 18, 2026 | Peptide | Peptide updated: Vilon | Vilon |
| Simple immune dipeptide |
| June 18, 2026 | Peptide | Peptide updated: Vladonix | Vladonix |
| Thymus bioregulator complex |
| June 18, 2026 | Peptide | Peptide updated: Thymalin | Thymalin |
| Thymus restoration peptide |
| June 18, 2026 | Peptide | Peptide updated: LL-37 | LL-37 |
| Antimicrobial defense peptide |
| June 18, 2026 | Peptide | Peptide updated: Hexapeptide-11 | Hexapeptide-11 |
| Cell renewal peptide |
| June 18, 2026 | Peptide | Peptide updated: Palmitoyl Tripeptide-5 | Palmitoyl Tripeptide-5 |
| Collagen booster |
| June 18, 2026 | Peptide | Peptide updated: Copper Peptide GHK-Cu | Copper Peptide GHK-Cu |
| Multi-functional skin peptide |
| June 18, 2026 | Peptide | Peptide updated: Snap-8 | Snap-8 |
| Enhanced Argireline |
| June 18, 2026 | Peptide | Peptide updated: Syn-Coll | Syn-Coll |
| Collagen synthesis peptide |
| June 18, 2026 | Peptide | Peptide updated: Matrixyl 3000 | Matrixyl 3000 |
| Advanced collagen booster |
| June 18, 2026 | Peptide | Peptide updated: Argireline (Acetyl Hexapeptide-8) | Argireline (Acetyl Hexapeptide-8) |
| Botox-like peptide |
| June 18, 2026 | Peptide | Peptide updated: Urolithin A | Urolithin A |
| Mitochondrial health compound |
| June 18, 2026 | Peptide | Peptide updated: Ovagen | Ovagen |
| Digestive system bioregulator |
| June 18, 2026 | Peptide | Peptide updated: Cortagen | Cortagen |
| Brain bioregulator |
| June 18, 2026 | Peptide | Peptide updated: Memantine | Memantine |
| NMDA antagonist |
| June 18, 2026 | Peptide | Peptide updated: RG3 (Rhodiola) | RG3 (Rhodiola) |
| Adaptogenic peptide |
| June 18, 2026 | Peptide | Peptide updated: FGL (Fibroblast Growth Loop) | FGL (Fibroblast Growth Loop) |
| NCAM mimetic |
| June 18, 2026 | Peptide | Peptide updated: Cortexin | Cortexin |
| Neuropeptide complex |
| June 18, 2026 | Peptide | Peptide updated: P21 (Adamax) | P21 (Adamax) |
| Neurogenic peptide |
| June 18, 2026 | Peptide | Peptide updated: NA-Semax-Amidate | NA-Semax-Amidate |
| Triple modified Semax |
| June 18, 2026 | Peptide | Peptide updated: Selank-Amidate | Selank-Amidate |
| Extended release Selank |
| June 18, 2026 | Peptide | Peptide updated: Semax-Amidate | Semax-Amidate |
| Extended release Semax |
| June 18, 2026 | Peptide | Peptide updated: HGH Fragment 176-191 | HGH Fragment 176-191 |
| Fat loss without GH effects |
| June 18, 2026 | Peptide | Peptide updated: Epithalon + Follistatin Stack | Epithalon + Follistatin Stack |
| Anti-aging performance combo |
| June 18, 2026 | Peptide | Peptide updated: YK-11 | YK-11 |
| Myostatin inhibitor |
| June 18, 2026 | Peptide | Peptide updated: ACE-031 | ACE-031 |
| Myostatin inhibitor |
| June 18, 2026 | Peptide | Peptide updated: TB4-FRAG | TB4-FRAG |
| TB-500 fragment |
| June 18, 2026 | Peptide | Peptide updated: GHRP-4 | GHRP-4 |
| Fourth generation GHRP |
| June 18, 2026 | Peptide | Peptide updated: Tesamorelin | Tesamorelin |
| GHRH for visceral fat |
| June 18, 2026 | Peptide | Peptide updated: Sermorelin | Sermorelin |
| GHRH for natural GH release |
| June 18, 2026 | Peptide | Peptide updated: Fragment 176-191 | Fragment 176-191 |
| HGH fragment for fat loss |
| June 18, 2026 | Peptide | Peptide updated: Leptin | Leptin |
| Satiety hormone |
| June 18, 2026 | Peptide | Peptide updated: Pramlintide | Pramlintide |
| Amylin analog for diabetes |
| June 18, 2026 | Peptide | Peptide updated: CagriSema | CagriSema |
| Combination therapy |
| June 18, 2026 | Peptide | Peptide updated: Retatrutide | Retatrutide |
| Investigational triple agonist (GIP/GLP-1/glucagon). TRIUMPH-1 Phase 3 (May 2026): 28.3% body weight loss at 80 weeks. FDA submission anticipated Q3–Q4 2026. |
| June 18, 2026 | Peptide | Peptide updated: Orforglipron | Orforglipron |
| Oral GLP-1 |
| June 18, 2026 | Peptide | Peptide updated: Dulaglutide | Dulaglutide |
| Weekly GLP-1 (Trulicity) |
| June 18, 2026 | Peptide | Peptide updated: Liraglutide | Liraglutide |
| FDA-approved GLP-1 for weight loss |
| June 18, 2026 | Peptide | Peptide updated: Ghrelinomimetic | Ghrelinomimetic |
| Appetite and healing support |
| June 18, 2026 | Peptide | Peptide updated: BPC-157 Stable | BPC-157 Stable |
| Stabilized BPC variant |
| June 18, 2026 | Peptide | Peptide updated: Pentosan Polysulfate | Pentosan Polysulfate |
| Joint and bladder support |
| June 18, 2026 | Peptide | Peptide updated: Larazotide | Larazotide |
| Gut permeability regulator |
| June 18, 2026 | Peptide | Peptide updated: Melanotan II | Melanotan II |
| Tanning, libido |
| June 18, 2026 | Peptide | Peptide updated: Copper Peptides | Copper Peptides |
| Skin regeneration |
| June 18, 2026 | Peptide | Peptide updated: Matrixyl (Palmitoyl Pentapeptide) | Matrixyl (Palmitoyl Pentapeptide) |
| Anti-aging skincare |
| June 18, 2026 | Peptide | Peptide updated: SS-31 (Elamipretide) | SS-31 (Elamipretide) |
| Mitochondrial optimization |
| June 18, 2026 | Peptide | Peptide updated: Humanin | Humanin |
| Mitochondrial protection, longevity |
| June 18, 2026 | Peptide | Peptide updated: Epitalon | Epitalon |
| Longevity, telomere support |
| June 18, 2026 | Peptide | Peptide updated: Cerebrolysin | Cerebrolysin |
| Neuroprotection, recovery |
| June 18, 2026 | Peptide | Peptide updated: NSI-189 | NSI-189 |
| Neurogenesis, depression |
| June 18, 2026 | Peptide | Peptide updated: Dihexa | Dihexa |
| Potent cognitive enhancer |
| June 18, 2026 | Peptide | Peptide updated: Selank | Selank |
| Anxiety reduction, focus |
| June 18, 2026 | Peptide | Peptide updated: Semax | Semax |
| Cognitive enhancement, focus, memory |
| June 18, 2026 | Peptide | Peptide updated: Hexarelin | Hexarelin |
| Potent GH releaser |
| June 18, 2026 | Peptide | Peptide updated: MK-677 (Ibutamoren) | MK-677 (Ibutamoren) |
| Oral GH secretagogue |
| June 18, 2026 | Peptide | Peptide updated: Ipamorelin | Ipamorelin |
| GH secretagogue, anti-aging |
| June 18, 2026 | Peptide | Peptide updated: CJC-1295 | CJC-1295 |
| Growth hormone, muscle mass, fat loss |
| June 18, 2026 | Peptide | Peptide updated: MOTS-c | MOTS-c |
| Mitochondrial optimization |
| June 18, 2026 | Peptide | Peptide updated: AOD-9604 | AOD-9604 |
| Fat loss, metabolic enhancement |
| June 18, 2026 | Peptide | Peptide updated: Tirzepatide | Tirzepatide |
| Dual GIP/GLP-1 agonist for weight loss |
| June 18, 2026 | Peptide | Peptide updated: Semaglutide | Semaglutide |
| Weight loss, blood sugar control |
| June 18, 2026 | Peptide | Peptide updated: Thymosin Alpha-1 | Thymosin Alpha-1 |
| Immune system support |
| June 18, 2026 | Peptide | Peptide updated: GHK-Cu | GHK-Cu |
| Wound healing, skin regeneration |
| June 18, 2026 | Peptide | Peptide updated: TB-500 | TB-500 |
| Tissue repair, flexibility, inflammation |
| June 18, 2026 | Peptide | Peptide updated: BPC-157 | BPC-157 |
| Healing & recovery, gut health |
| June 15, 2026 | Source | Source updated: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)pubmed.ncbi.nlm.nih.gov/9742976/ | — |
| The Lancet |
| June 15, 2026 | Source | New source added: UKPDS 33 Study Summary — Wiki Journal Clubwikijournalclub.org/wiki/UKPDS_33 | — |
| Wiki Journal Club |
| June 15, 2026 | Source | New source added: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) — The Lancet 1998thelancet.com/journals/lancet/article/PIIS0140-6736(98)07019-6… | — |
| The Lancet |
| June 15, 2026 | Source | New source added: Blood Glucose Control Studies for Type 1 Diabetes: DCCT and EDIC — NIDDKniddk.nih.gov/about-niddk/research-areas/diabetes/blood-glucos… | — |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| June 15, 2026 | Source | New source added: Insulin: Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy — Endotext (NCBI Bookshelf NBK278938)ncbi.nlm.nih.gov/books/NBK278938/ | — |
| MDText.com / NCBI Bookshelf |
| June 15, 2026 | Source | New source added: Lantus (insulin glargine injection) Prescribing Information — FDA accessdataaccessdata.fda.gov/drugsatfda_docs/label/2019/021081s072lbl.pdf | — |
| U.S. Food and Drug Administration / Sanofi |
| June 15, 2026 | Source | New source added: HUMULIN R (insulin human) Prescribing Information — DailyMeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b519bd83-038c-4ec5-a… | — |
| U.S. National Library of Medicine / DailyMed |
| June 15, 2026 | Peptide | New peptide added: Insulin | Insulin |
| The foundational peptide hormone for glycemic management in type 1 and type 2 diabetes mellitus. |
| June 15, 2026 | Source | Source updated: Bivalirudin during primary PCI in acute myocardial infarction (HORIZONS-AMI)pubmed.ncbi.nlm.nih.gov/18499566/ | — |
| New England Journal of Medicine |
| June 15, 2026 | Source | New source added: Safety and Efficacy of Bivalirudin with Glycoprotein IIb/IIIa for High-Risk Percutaneous Coronary Intervention (Deshpande et al., Indian Heart Journal 2012)pmc.ncbi.nlm.nih.gov/articles/PMC3860907/ | — |
| Indian Heart Journal / PMC |
| June 15, 2026 | Source | New source added: Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trialsahajournals.org/doi/10.1161/CIRCULATIONAHA.123.063946 | — |
| Circulation (American Heart Association) |
| June 15, 2026 | Source | New source added: Bivalirudin — Wikidoc (chemical structure, pharmacokinetics, approval history)wikidoc.org/index.php/Bivalirudin | — |
| Wikidoc |
| June 15, 2026 | Source | New source added: Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes — MATRIX Trial (Valgimigli et al., NEJM 2015)nejm.org/doi/full/10.1056/NEJMoa1507854 | — |
| New England Journal of Medicine |
| June 15, 2026 | Source | New source added: Bivalirudin for Patients with Acute Coronary Syndromes — ACUITY Trial (Stone et al., NEJM 2006)nejm.org/doi/full/10.1056/NEJMoa062437 | — |
| New England Journal of Medicine |
| June 15, 2026 | Source | New source added: HORIZONS-AMI Trial Summary — Wiki Journal Club (Stone et al., NEJM 2008; PMID 18499566)wikijournalclub.org/wiki/HORIZONS-AMI | — |
| Wiki Journal Club |
| June 15, 2026 | Source | New source added: Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial (Lincoff et al., JAMA 2003)jamanetwork.com/journals/jama/fullarticle/195991 | — |
| JAMA (American Medical Association) |
| June 15, 2026 | Source | New source added: DailyMed: ANGIOMAX (bivalirudin) for injection — FDA Prescribing Informationdailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f133813-f74e-4508-b… | — |
| U.S. National Library of Medicine / FDA |
| June 15, 2026 | Peptide | New peptide added: Bivalirudin | Bivalirudin |
| FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients. |
| June 15, 2026 | Source | New source added: Exenatide once weekly: clinical outcomes and patient satisfaction (DURATION-1 data)pmc.ncbi.nlm.nih.gov/articles/PMC2943223/ | — |
| Drug Design, Development and Therapy |
| June 15, 2026 | Source | New source added: Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weekspmc.ncbi.nlm.nih.gov/articles/PMC3593159/ | — |
| Diabetes, Obesity and Metabolism |
| June 15, 2026 | Source | New source added: Evolution of Exenatide as a Diabetes Therapeuticpmc.ncbi.nlm.nih.gov/articles/PMC3664512/ | — |
| BioMed Research International |
| June 15, 2026 | Source | New source added: Exenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies (DURATION program review)pmc.ncbi.nlm.nih.gov/articles/PMC3303092/ | — |
| Clinical Therapeutics |
| June 15, 2026 | Source | New source added: EXSCEL Trial Summary — American College of Cardiologyacc.org/Latest-in-Cardiology/Clinical-Trials/2017/10/03/… | — |
| American College of Cardiology |
| June 15, 2026 | Source | New source added: Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL trial)nejm.org/doi/full/10.1056/NEJMoa1612917 | — |
| New England Journal of Medicine |
| June 15, 2026 | Source | New source added: Highlights of Prescribing Information — BYDUREON BCise (exenatide extended-release), NDA 022200 (2024 label)accessdata.fda.gov/drugsatfda_docs/label/2024/022200s035lbl.pdf | — |
| U.S. Food and Drug Administration |
| June 15, 2026 | Source | New source added: BYETTA (exenatide) Prescribing Information — FDA/accessdata (2020 label, NDA 021773)accessdata.fda.gov/drugsatfda_docs/label/2020/021773s043lbl.pdf | — |
| U.S. Food and Drug Administration |
| June 15, 2026 | Peptide | New peptide added: Exenatide | Exenatide |
| FDA-approved GLP-1 receptor agonist for type 2 diabetes; the first incretin mimetic approved in the US. |
| June 15, 2026 | Source | New source added: Desmopressin for nocturnal enuresis in children (Cochrane Review)pubmed.ncbi.nlm.nih.gov/12137645/ | — |
| Cochrane Database of Systematic Reviews / PubMed |
| June 15, 2026 | Source | New source added: Modern Approach in Treatment of Diabetes Insipiduspmc.ncbi.nlm.nih.gov/articles/PMC7214070/ | — |
| PMC / NLM |
| June 15, 2026 | Source | New source added: Desmopressin in combination with anticholinergic agents in the treatment of nocturnal enuresis: a systematic review and meta-analysispmc.ncbi.nlm.nih.gov/articles/PMC10620680/ | — |
| PMC / NLM |
| June 15, 2026 | Source | New source added: A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?pmc.ncbi.nlm.nih.gov/articles/PMC12292229/ | — |
| MDPI Biomolecules |
| June 15, 2026 | Source | New source added: DDAVP (desmopressin acetate) Tablets — Prescribing Informationdailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d55baa9-2b62-469c-9… | — |
| U.S. National Library of Medicine / DailyMed |
| June 15, 2026 | Source | New source added: DDAVP (desmopressin acetate) Injection — Full Prescribing Informationdailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=651f6fee-a2c7-… | — |
| U.S. National Library of Medicine / DailyMed |
| June 15, 2026 | Peptide | New peptide added: Desmopressin | Desmopressin |
| Synthetic ADH analog (DDAVP) FDA-approved for diabetes insipidus, nocturnal enuresis, and bleeding disorders |
| June 15, 2026 | Source | New source added: Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumorspubmed.ncbi.nlm.nih.gov/23462624/ | — |
| Drugs Today (Barcelona) |
| June 15, 2026 | Source | New source added: Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegalypmc.ncbi.nlm.nih.gov/articles/PMC4996868/ | — |
| PubMed Central |
| June 15, 2026 | Source | New source added: Clinical use of pasireotide for Cushing's disease in adultspmc.ncbi.nlm.nih.gov/articles/PMC4370333/ | — |
| PubMed Central |
| June 15, 2026 | Source | New source added: Pasireotide — a novel somatostatin receptor ligand after 20 years of usepmc.ncbi.nlm.nih.gov/articles/PMC9156514/ | — |
| PubMed Central |
| June 15, 2026 | Source | New source added: Pasireotide versus octreotide or lanreotide in inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trialthelancet.com/journals/landia/article/PIIS2213-8587(14)70169-X… | — |
| Lancet Diabetes and Endocrinology |
| June 15, 2026 | Source | New source added: A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease (B2305)nejm.org/doi/full/10.1056/NEJMoa1105743 | — |
| New England Journal of Medicine |
| June 15, 2026 | Source | New source added: DailyMed: SIGNIFOR (pasireotide diaspartate) injection — Full Prescribing Informationdailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a25fc-a5a3-0c82-e… | — |
| U.S. National Library of Medicine / FDA |
| June 15, 2026 | Source | New source added: DailyMed: SIGNIFOR LAR (pasireotide) for injectable suspension — Full Prescribing Informationdailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0aad470-3f38-af97-e… | — |
| U.S. National Library of Medicine / FDA |
| June 15, 2026 | Peptide | New peptide added: Pasireotide | Pasireotide |
| Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly. |
| June 15, 2026 | Source | New source added: Treatment of neuroendocrine tumors: new recommendations based on the CLARINET studypmc.ncbi.nlm.nih.gov/articles/PMC4709401/ | — |
| Cancer Treatment Reviews |
| June 15, 2026 | Source | New source added: Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trialpubmed.ncbi.nlm.nih.gov/16918950/ | — |
| Clinical Endocrinology (Oxford) |
| June 15, 2026 | Source | New source added: Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (ELECT): A Randomized, Double-Blind, Placebo-Controlled Trialpubmed.ncbi.nlm.nih.gov/27214300/ | — |
| Endocrine Practice |
| June 15, 2026 | Source | New source added: Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension studypubmed.ncbi.nlm.nih.gov/33052555/ | — |
| Endocrine |
| June 15, 2026 | Source | New source added: Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors (CLARINET trial)pubmed.ncbi.nlm.nih.gov/25014687/ | — |
| New England Journal of Medicine |
| June 15, 2026 | Source | New source added: SOMATULINE DEPOT (lanreotide acetate) - Full Prescribing Information, DailyMeddailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6e4a41fd-a753-… | — |
| Ipsen Biopharmaceuticals / U.S. National Library of Medicine |
| June 15, 2026 | Peptide | New peptide added: Lanreotide | Lanreotide |
| FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome |
| June 15, 2026 | Source | New source added: Octreotide Long-Acting Repeatable in the Treatment of Neuroendocrine Tumors: Patient Selection and Perspectivespmc.ncbi.nlm.nih.gov/articles/PMC5723116/ | — |
| OncoTargets and Therapy |
| June 15, 2026 | Source | New source added: Efficacy of Octreotide Long-Acting Repeatable in Neuroendocrine Tumors: RADIANT-2 Placebo Arm Post Hoc Analysispmc.ncbi.nlm.nih.gov/articles/PMC4609826/ | — |
| Oncologist |
| June 15, 2026 | Source | New source added: A Prospective Multicentre Study to Investigate the Efficacy, Safety and Tolerability of Octreotide LAR in the Primary Therapy of Patients with Acromegalypmc.ncbi.nlm.nih.gov/articles/PMC1974838/ | — |
| European Journal of Endocrinology |
| June 15, 2026 | Source | New source added: Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1)pmc.ncbi.nlm.nih.gov/articles/PMC5895095/ | — |
| New England Journal of Medicine |
| June 15, 2026 | Source | New source added: Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survivalpubmed.ncbi.nlm.nih.gov/26731483/ | — |
| Neuroendocrinology / Karger |
| June 15, 2026 | Source | New source added: DailyMed: Octreotide Acetate for Injectable Suspension (Sandostatin LAR Depot) — Full Prescribing Informationdailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9739ea6-74de-4a41-a… | — |
| NLM / FDA |
| June 15, 2026 | Source | New source added: DailyMed: Octreotide Acetate Injection, Solution (Sandostatin) — Full Prescribing Informationdailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ce2fc1e-7520-4d04-b… | — |
| NLM / FDA |
| June 15, 2026 | Peptide | New peptide added: Octreotide | Octreotide |
| FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988 |
| June 14, 2026 | FDA approval | New FDA-approved peptide: Bremelanotidefda.gov/news-events/press-announcements/fda-approves-new… | Bremelanotide |
| Vyleesi — Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women |
| June 14, 2026 | Peptide | Peptide updated: PT-141 | PT-141 |
| Sexual function peptide |
| June 14, 2026 | Source | New source added: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 (Retatrutide) Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweightclinicaltrials.gov/study/NCT05929079 | — |
| ClinicalTrials.gov |
| June 14, 2026 | Source | New source added: A Phase 3 Event-Driven Study of Retatrutide on Major Adverse Cardiovascular and Kidney Events in Participants With BMI >=27 and Established Cardiovascular or Kidney Diseaseclinicaltrials.gov/study/NCT06383390 | — |
| ClinicalTrials.gov |
| June 14, 2026 | Source | New source added: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 (Retatrutide) Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-1)clinicaltrials.gov/study/NCT05929066 | — |
| ClinicalTrials.gov |
| June 14, 2026 | Source | New source added: LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trialpubmed.ncbi.nlm.nih.gov/36354040/ | — |
| The Lancet |
| June 14, 2026 | Source | New source added: LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptpubmed.ncbi.nlm.nih.gov/35985340/ | — |
| Cell Metabolism |
| June 14, 2026 | Source | New source added: Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialpubmed.ncbi.nlm.nih.gov/38858523/ | — |
| Nature Medicine |
| June 14, 2026 | Source | New source added: Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trialpubmed.ncbi.nlm.nih.gov/37385280/ | — |
| The Lancet |
| June 14, 2026 | Source | New source added: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trialpubmed.ncbi.nlm.nih.gov/37366315/ | — |
| New England Journal of Medicine |
| June 13, 2026 | Source | New source added: Detailed Results of a Clinical Study of Vladonixqisupplements.com/blogs/news/detailed-results-of-a-clinical-study-… | — |
| Qi Supplements |
| June 13, 2026 | Source | New source added: Vladonix A-6 Thymus Natural Peptide Bioregulator (product page)vita-stream.com/a-6-thymus-peptide-bioregulator-vladonix/ | — |
| Vita-Stream |
| June 13, 2026 | Source | New source added: Thymus Extract — Uses, Dosage, Side Effects, Interactionsrxlist.com/thymus_extract/supplements.htm | — |
| RxList / WebMD |
| June 13, 2026 | Source | New source added: Vladimir Khavinson — Wikipediaen.wikipedia.org/wiki/Vladimir_Khavinson | — |
| June 13, 2026 | Source | New source added: Peptide bioregulators: A new class of geroprotectors, report 2. The results of clinical trialslink.springer.com/article/10.1134/S2079057014040122 | — |
| Advances in Gerontology / Springer |
| June 13, 2026 | Source | New source added: Peptides of pineal gland and thymus prolong human life (NeL.edu abstract)nel.edu/peptides-of-pineal-gland-and-thymus-prolong-huma… | — |
| Neuro Endocrinology Letters |
| June 13, 2026 | Source | New source added: Peptides of pineal gland and thymus prolong human lifepubmed.ncbi.nlm.nih.gov/14523363/ | — |
| Neuro Endocrinology Letters |
| June 13, 2026 | Source | New source added: Clinical Study of the Biologically Active Peptide Bioregulator Vladonixantiaging-systems.com/articles/clinical-study-of-the-biologically-acti… | — |
| Antiaging Systems |
| June 13, 2026 | Source | New source added: Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Linepubmed.ncbi.nlm.nih.gov/35408963/ | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellituspubmed.ncbi.nlm.nih.gov/18306698/ | — |
| Advances in Gerontology |
| June 13, 2026 | Source | New source added: The effect of vilon (Lys-Glu) on 1,2-dimethylhydrazine-induced neoplasiapubmed.ncbi.nlm.nih.gov/16308980/ | — |
| Voprosy Onkologii |
| June 13, 2026 | Source | New source added: Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technologypubmed.ncbi.nlm.nih.gov/12360356/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in ratspubmed.ncbi.nlm.nih.gov/11586406/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Effect of peptide Lys-Glu on interleukin-2 gene expression in lymphocytespubmed.ncbi.nlm.nih.gov/11177276/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of micepubmed.ncbi.nlm.nih.gov/10944717/ | — |
| Doklady Biological Sciences |
| June 13, 2026 | Source | New source added: Effect of vilon on biological age and lifespan in micepubmed.ncbi.nlm.nih.gov/11140587/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Urolithin A and nicotinamide riboside differentially regulate innate immune defenses and metabolism in human microglial cellspmc.ncbi.nlm.nih.gov/articles/PMC11631940/ | — |
| Frontiers in Aging Neuroscience |
| June 13, 2026 | Source | New source added: Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the populationpmc.ncbi.nlm.nih.gov/articles/PMC8821002/ | — |
| European Journal of Clinical Nutrition |
| June 13, 2026 | Source | New source added: Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trialnature.com/articles/s43587-025-00996-x | — |
| Nature Aging |
| June 13, 2026 | Source | New source added: Targeting aging with urolithin A in humans: A systematic reviewpubmed.ncbi.nlm.nih.gov/39002645/ | — |
| Ageing Research Reviews |
| June 13, 2026 | Source | New source added: Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adultscell.com/cell-reports-medicine/fulltext/S2666-3791(22)001… | — |
| Cell Reports Medicine |
| June 13, 2026 | Source | New source added: Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trialjamanetwork.com/journals/jamanetworkopen/fullarticle/2788244 | — |
| JAMA Network Open |
| June 13, 2026 | Source | New source added: The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humansnature.com/articles/s42255-019-0073-4 | — |
| Nature Metabolism |
| June 13, 2026 | Source | New source added: Thyreogen Peptide: Thyroid Bioregulator for Endocrine Supportbioregulatorpeptides.co.uk/thyreogen/ | — |
| June 13, 2026 | Source | New source added: Peptide bioregulators: A new class of geroprotectors, report 2. The results of clinical trialslink.springer.com/article/10.1134/S2079057014040122 | — |
| Advances in Gerontology |
| June 13, 2026 | Source | New source added: Safety of Natural Peptide Bioregulatorsantiaging-nutrition.com/articles/safety-of-natural-peptide-bioregulators… | — |
| June 13, 2026 | Source | New source added: Influence of Peptide Bioregulators on Morphology of Parenchymatous Organsantiaging-systems.com/articles/influence-of-peptide-bioregulators-on-m… | — |
| June 13, 2026 | Source | New source added: Thyreogen: The Thyroid Gland Peptide Bioregulatorjaycampbell.com/bioregulators/thyreogen-the-thyroid-gland-peptid… | — |
| June 13, 2026 | Source | New source added: Vladimir Khavinson — Wikipediaen.wikipedia.org/wiki/Vladimir_Khavinson | — |
| June 13, 2026 | Source | New source added: Peptide bioregulation of aging: results and prospectspubmed.ncbi.nlm.nih.gov/19830585/ | — |
| Biogerontology |
| June 13, 2026 | Source | New source added: Peptide bioregulator efficacy in the correction of reduced thyroid gland function in the residents of Magadan Regionpubmed.ncbi.nlm.nih.gov/16075681/ | — |
| Advances in Gerontology |
| June 13, 2026 | Source | New source added: Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction (NCT05984134)clinicaltrials.gov/study/NCT05984134 | — |
| June 13, 2026 | Source | New source added: Thymosin β4 inhibits TNF-α-induced NF-κB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILKpmc.ncbi.nlm.nih.gov/articles/PMC3101037/ | — |
| PLoS ONE / PMC |
| June 13, 2026 | Source | New source added: Thymosin β4 Promotes Dermal Healingpubmed.ncbi.nlm.nih.gov/27450738/ | — |
| Vitamins and Hormones / Elsevier |
| June 13, 2026 | Source | New source added: Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healingpubmed.ncbi.nlm.nih.gov/17495250/ | — |
| June 13, 2026 | Source | New source added: Progress on the Function and Application of Thymosin β4pmc.ncbi.nlm.nih.gov/articles/PMC8724243/ | — |
| Frontiers in Endocrinology |
| June 13, 2026 | Source | New source added: A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteerspubmed.ncbi.nlm.nih.gov/34346165/ | — |
| British Journal of Clinical Pharmacology |
| June 13, 2026 | Source | New source added: Thymosin beta4 accelerates wound healingpubmed.ncbi.nlm.nih.gov/10469335/ | — |
| Journal of Investigative Dermatology |
| June 13, 2026 | Source | New source added: Thymosin beta4: actin-sequestering protein moonlights to repair injured tissuespubmed.ncbi.nlm.nih.gov/16099219/ | — |
| Trends in Molecular Medicine / Elsevier |
| June 13, 2026 | Source | New source added: Safety Assessment of Palmitoyl Oligopeptides Ingredients as Used in Cosmeticscir-safety.org/panelbook/safety-assessment-palmitoyl-oligopepti… | — |
| Cosmetic Ingredient Review (CIR) |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5: What Can It Do for Your Skin?thedermreview.com/palmitoyl-tripeptide-5/ | — |
| The Dermatology Review |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5 Ingredient Profileincidecoder.com/ingredients/palmitoyl-tripeptide-5 | — |
| INCIDecoder |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5: Research in Skin Cell Proliferation and Rejuvenationcorepeptides.com/palmitoyl-tripeptide-5-syn-coll-peptide-research… | — |
| Core Peptides |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5 (Syn-Coll) Peptide and Collagen Productionbiotechpeptides.com/2022/07/25/palmitoyl-tripeptide-5-syn-coll-pepti… | — |
| Biotech Peptides |
| June 13, 2026 | Source | New source added: Syn-Coll Tripeptide and Skin Cell Architecturebiotechpeptides.com/2025/10/22/syn-coll-tripeptide-and-skin-cell-arc… | — |
| Biotech Peptides |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5: Collagen Booster Profilepeptidejournal.org/peptides/palmitoyl-tripeptide-5-collagen-booster… | — |
| PeptideJournal.org |
| June 13, 2026 | Source | New source added: The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of actionpmc.ncbi.nlm.nih.gov/articles/PMC7247319/ | — |
| Journal of Biological Chemistry |
| June 13, 2026 | Source | New source added: A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome (TAZPOWER) — NCT03098797clinicaltrials.gov/study/NCT03098797 | — |
| ClinicalTrials.gov |
| June 13, 2026 | Source | New source added: Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approvalpubmed.ncbi.nlm.nih.gov/41260682/ | — |
| Drug Discovery and Therapeutics |
| June 13, 2026 | Source | New source added: Long-term treatment with Elamipretide enhances healthy aging phenotypes in micepmc.ncbi.nlm.nih.gov/articles/PMC9562127/ | — |
| Aging Pathobiology and Therapeutics |
| June 13, 2026 | Source | New source added: SS-31 and NMN: Two paths to improve metabolism and function in aged heartspmc.ncbi.nlm.nih.gov/articles/PMC7576234/ | — |
| Aging Cell |
| June 13, 2026 | Source | New source added: Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretidepubmed.ncbi.nlm.nih.gov/29217757/ | — |
| Circulation: Heart Failure |
| June 13, 2026 | Source | New source added: FORZINITY (elamipretide hydrochloride) Prescribing Informationdailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=146bf34c-76f2-48db-ac0… | — |
| U.S. National Library of Medicine / Stealth BioTherapeutics |
| June 13, 2026 | Source | New source added: Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potentialpmc.ncbi.nlm.nih.gov/articles/PMC11816484/ | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Functional effects of splenin32-34 on antibody formation in immunosuppressed micepubmed.ncbi.nlm.nih.gov/3551932/ | — |
| Biomedica Biochimica Acta |
| June 13, 2026 | Source | New source added: Thymopentin and splenopentin as immunomodulators. Current statuspubmed.ncbi.nlm.nih.gov/9638477/ | — |
| Immunologic Research |
| June 13, 2026 | Source | New source added: Splenopentin (DAc-SP5)--influence on engraftment and graft-vs-host reaction after non-H-2 bone marrow transplantation in micepubmed.ncbi.nlm.nih.gov/2083570/ | — |
| Experimental and Clinical Endocrinology |
| June 13, 2026 | Source | New source added: Diacetyl-splenopentin (BCH 069) did not affect the concentrations of various hormones in menpubmed.ncbi.nlm.nih.gov/2083571/ | — |
| Experimental and Clinical Endocrinology |
| June 13, 2026 | Source | New source added: Clinical, biochemical and immunological effectiveness of diacetyl-splenopentin (BCH 069) in hay feverpubmed.ncbi.nlm.nih.gov/2251976/ | — |
| Allergologia et Immunopathologia |
| June 13, 2026 | Source | New source added: The effect of splenopentin (DA SP-5) on in vitro myelopoiesis and on AZT-induced bone marrow toxicitypubmed.ncbi.nlm.nih.gov/8505137/ | — |
| International Journal of Immunopharmacology |
| June 13, 2026 | Source | New source added: Splenopentin (DAc-SP-5) accelerates the restoration of myelopoietic and immune systems after sublethal radiation in micepubmed.ncbi.nlm.nih.gov/2292457/ | — |
| International Journal of Immunopharmacology |
| June 13, 2026 | Source | New source added: Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleenpmc.ncbi.nlm.nih.gov/articles/PMC345168/ | — |
| Proceedings of the National Academy of Sciences USA |
| June 13, 2026 | Source | New source added: Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometrylink.springer.com/article/10.1186/s40543-020-00232-8 | — |
| Journal of Analytical Science and Technology |
| June 13, 2026 | Source | New source added: A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cellspubmed.ncbi.nlm.nih.gov/9006897/ | — |
| Journal of Biological Chemistry |
| June 13, 2026 | Source | New source added: The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled studypubmed.ncbi.nlm.nih.gov/23417317/ | — |
| American Journal of Clinical Dermatology |
| June 13, 2026 | Source | New source added: An Open Label Clinical Trial of a Peptide Treatment Serum and Supporting Regimen Designed to Improve the Appearance of Aging Facial Skinjddonline.com/articles/an-open-label-clinical-trial-of-a-pepti… | — |
| Journal of Drugs in Dermatology |
| June 13, 2026 | Source | New source added: Peptide-pro complex serum: Investigating effects on aged skinpmc.ncbi.nlm.nih.gov/articles/PMC10084013/ | — |
| June 13, 2026 | Source | New source added: Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Reviewpmc.ncbi.nlm.nih.gov/articles/PMC11762834/ | — |
| MDPI |
| June 13, 2026 | Source | New source added: Cosmeceutical Peptides in the Framework of Sustainable Wellness Economypmc.ncbi.nlm.nih.gov/articles/PMC7662462/ | — |
| Frontiers in Chemistry |
| June 13, 2026 | Source | New source added: Sermorelin - Wikipediaen.wikipedia.org/wiki/Sermorelin | — |
| Wikipedia |
| June 13, 2026 | Source | New source added: What Should Athletes Know About Sermorelin?usada.org/spirit-of-sport/athletes-know-sermorelin/ | — |
| United States Anti-Doping Agency (USADA) |
| June 13, 2026 | Source | New source added: Sermorelin Acetate: Prescribing Informationrxlist.com/sermorelin-acetate-drug.htm | — |
| RxList / WebMD |
| June 13, 2026 | Source | New source added: Growth Hormone and Aging - Endotextncbi.nlm.nih.gov/books/NBK279163/ | — |
| NCBI Bookshelf (Endotext / MDText.com) |
| June 13, 2026 | Source | New source added: Treating age-related changes in somatotrophic hormones, sleep, and cognitionpmc.ncbi.nlm.nih.gov/articles/PMC3181657/ | — |
| Dialogues in Clinical Neuroscience |
| June 13, 2026 | Source | New source added: Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal malespmc.ncbi.nlm.nih.gov/articles/PMC7108996/ | — |
| Translational Andrology and Urology |
| June 13, 2026 | Source | New source added: Endocrine and Metabolic Effects of Long-Term Administration of [Nle27]Growth Hormone-Releasing Hormone-(1-29)-NH2 in Age-Advanced Men and Womenacademic.oup.com/jcem/article/82/5/1472/2823341 | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 13, 2026 | Source | New source added: Zadaxin (Thymalfasin): Side Effects, Uses, Dosage, Interactions, Warningsrxlist.com/zadaxin-drug.htm | — |
| June 13, 2026 | Source | New source added: Thymosin alpha 1 reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cellspmc.ncbi.nlm.nih.gov/articles/PMC7314217/ | — |
| June 13, 2026 | Source | New source added: Immune Modulation with Thymosin Alpha 1 Treatmentpubmed.ncbi.nlm.nih.gov/27450734/ | — |
| June 13, 2026 | Source | New source added: Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis of 27 randomized controlled trialspubmed.ncbi.nlm.nih.gov/31326719/ | — |
| PubMed / NCBI |
| June 13, 2026 | Source | New source added: Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled studypubmed.ncbi.nlm.nih.gov/10607256/ | — |
| June 13, 2026 | Source | New source added: Thymosin-alpha1 for Sepsis Management: A Systematic Review and Meta-Analysis of 1972 Patientspmc.ncbi.nlm.nih.gov/articles/PMC12792209/ | — |
| June 13, 2026 | Source | New source added: Thymosin alpha 1: A comprehensive review of the literaturepmc.ncbi.nlm.nih.gov/articles/PMC7747025/ | — |
| Vitamins and Hormones, Academic Press |
| June 13, 2026 | Source | New source added: THYMALIN (Thymus Extract) product page — RuPharmarupharma.com/thymalin-thymus-extract/ | — |
| June 13, 2026 | Source | New source added: Natural and synthetic thymic peptides as therapeutics for immune dysfunctionsciencedirect.com/science/article/abs/pii/S0192056197000581 | — |
| International Journal of Immunopharmacology |
| June 13, 2026 | Source | New source added: Peptide bioregulators: A new class of geroprotectors, report 2. The results of clinical trialslink.springer.com/article/10.1134/S2079057014040122 | — |
| Advances in Gerontology (Springer Nature) |
| June 13, 2026 | Source | New source added: Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patientslink.springer.com/article/10.1134/S2079057021040068 | — |
| Advances in Gerontology (Springer Nature) |
| June 13, 2026 | Source | New source added: The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19pmc.ncbi.nlm.nih.gov/articles/PMC10488166/ | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19pmc.ncbi.nlm.nih.gov/articles/PMC7877506/ | — |
| Stem Cell Reviews and Reports |
| June 13, 2026 | Source | New source added: Peptides of pineal gland and thymus prolong human lifepubmed.ncbi.nlm.nih.gov/14523363/ | — |
| Neuro Endocrinology Letters |
| June 13, 2026 | Source | New source added: FORTEO (teriparatide) Prescribing Information — DailyMeddailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1b007339-dd0d-… | — |
| U.S. National Library of Medicine / FDA |
| June 13, 2026 | Source | New source added: Teriparatide - StatPearlsncbi.nlm.nih.gov/books/NBK559248/ | — |
| NCBI Bookshelf / StatPearls |
| June 13, 2026 | Source | New source added: The why and how of sequential and combination therapy in osteoporosis: a review of the current evidencepmc.ncbi.nlm.nih.gov/articles/PMC10118820/ | — |
| June 13, 2026 | Source | New source added: Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic reviewpmc.ncbi.nlm.nih.gov/articles/PMC11026046/ | — |
| June 13, 2026 | Source | New source added: Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updatespmc.ncbi.nlm.nih.gov/articles/PMC9465003/ | — |
| June 13, 2026 | Source | New source added: Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosispubmed.ncbi.nlm.nih.gov/18003959/ | — |
| New England Journal of Medicine |
| June 13, 2026 | Source | New source added: Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trialpubmed.ncbi.nlm.nih.gov/29129436/ | — |
| The Lancet |
| June 13, 2026 | Source | New source added: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis (Fracture Prevention Trial)pubmed.ncbi.nlm.nih.gov/11346808/ | — |
| New England Journal of Medicine |
| June 13, 2026 | Source | New source added: Thymosin beta-4 — Wikipediaen.wikipedia.org/wiki/Thymosin_beta-4 | — |
| Wikimedia Foundation |
| June 13, 2026 | Source | New source added: TB-500 — Wikipediaen.wikipedia.org/wiki/TB-500 | — |
| Wikimedia Foundation |
| June 13, 2026 | Source | New source added: Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosispubmed.ncbi.nlm.nih.gov/23739235/ | — |
| Kidney International |
| June 13, 2026 | Source | New source added: A Dose Response Study of Thymosin β4 for the Treatment of Acute Strokepmc.ncbi.nlm.nih.gov/articles/PMC4177939/ | — |
| Journal of Neurological Sciences |
| June 13, 2026 | Source | New source added: RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye modelpmc.ncbi.nlm.nih.gov/articles/PMC6043477/ | — |
| Scientific Reports |
| June 13, 2026 | Source | New source added: Preventive and therapeutic effects of thymosin β4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosispmc.ncbi.nlm.nih.gov/articles/PMC5085123/ | — |
| Oncotarget |
| June 13, 2026 | Source | New source added: A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction (NCT01311518)clinicaltrials.gov/study/NCT01311518 | — |
| ClinicalTrials.gov |
| June 13, 2026 | Source | New source added: Progress on the Function and Application of Thymosin β4pmc.ncbi.nlm.nih.gov/articles/PMC8724243/ | — |
| Frontiers in Endocrinology |
| June 13, 2026 | Source | New source added: Thymosin β4 Promotes Dermal Healingpubmed.ncbi.nlm.nih.gov/27450738/ | — |
| Vitamins and Hormones |
| June 13, 2026 | Source | New source added: Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healingpubmed.ncbi.nlm.nih.gov/17495250/ | — |
| Annals of the New York Academy of Sciences |
| June 13, 2026 | Source | New source added: 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trialpmc.ncbi.nlm.nih.gov/articles/PMC9820614/ | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applicationspubmed.ncbi.nlm.nih.gov/22074294/ | — |
| Expert Opinion on Biological Therapy |
| June 13, 2026 | Source | New source added: Biological activities of thymosin beta4 defined by active sites in short peptide sequencespubmed.ncbi.nlm.nih.gov/20179146/ | — |
| FASEB Journal |
| June 13, 2026 | Source | New source added: The actin binding site on thymosin beta4 promotes angiogenesispubmed.ncbi.nlm.nih.gov/14500546/ | — |
| FASEB Journal |
| June 13, 2026 | Source | New source added: YK-11 — Wikipediaen.wikipedia.org/wiki/YK-11 | — |
| Wikimedia Foundation |
| June 13, 2026 | Source | New source added: Detection of selective androgen receptor modulator YK-11 in a doping control sample (Sobolevsky et al., 2024)pubmed.ncbi.nlm.nih.gov/37946705/ | — |
| Drug Testing and Analysis |
| June 13, 2026 | Source | New source added: Studies on the in vivo metabolism of the SARM YK11: identification and characterization of metabolites potentially useful for doping controls (Piper et al., 2018)pubmed.ncbi.nlm.nih.gov/30379415/ | — |
| Drug Testing and Analysis |
| June 13, 2026 | Source | New source added: YK11 promotes osteogenic differentiation of BMSCs and repair of bone defects (Wang et al., 2025)pubmed.ncbi.nlm.nih.gov/39660819/ | — |
| Journal of Molecular Endocrinology |
| June 13, 2026 | Source | New source added: Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis (Lee et al., 2021)pubmed.ncbi.nlm.nih.gov/33588136/ | — |
| Biochemical and Biophysical Research Communications |
| June 13, 2026 | Source | New source added: Selective androgen receptor modulator YK11 regulates myogenic differentiation of C2C12 myoblasts by follistatin expression (Kanno et al., 2013)pubmed.ncbi.nlm.nih.gov/23995658/ | — |
| Biological and Pharmaceutical Bulletin |
| June 13, 2026 | Source | New source added: YK11 is a partial agonist of the androgen receptor (Kanno et al., 2011)pubmed.ncbi.nlm.nih.gov/21372378/ | — |
| Biological and Pharmaceutical Bulletin |
| June 13, 2026 | Source | New source added: NCT06917404 – A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium in Knee Osteoarthritis Painclinicaltrials.gov/study/NCT06917404 | — |
| June 13, 2026 | Source | New source added: Pentosan Polysulfate: Mechanism, Adverse Effects, Contraindications, and Dosageurology-textbook.com/pps.html | — |
| June 13, 2026 | Source | New source added: Pentosan Polysulfate Maculopathy - StatPearlsncbi.nlm.nih.gov/books/NBK589706/ | — |
| NCBI Bookshelf / StatPearls |
| June 13, 2026 | Source | New source added: Pentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissuespmc.ncbi.nlm.nih.gov/articles/PMC10132487/ | — |
| June 13, 2026 | Source | New source added: Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trialpubmed.ncbi.nlm.nih.gov/38777590/ | — |
| June 13, 2026 | Source | New source added: The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot studypubmed.ncbi.nlm.nih.gov/36879559/ | — |
| June 13, 2026 | Source | New source added: Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double-blind, placebo-controlled, randomized studypubmed.ncbi.nlm.nih.gov/34336239/ | — |
| June 13, 2026 | Source | New source added: Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trialspubmed.ncbi.nlm.nih.gov/30849922/ | — |
| Current Medical Research and Opinion |
| June 13, 2026 | Source | New source added: Pegzilarginase — Wikipediaen.wikipedia.org/wiki/Pegzilarginase | — |
| June 13, 2026 | Source | New source added: Pegzilarginase for Arginase-1 deficiency — NIHR Evidence Scanio.nihr.ac.uk/wp-content/uploads/2022/01/22745-Pegzilarginase-… | — |
| National Institute for Health Research (NIHR) |
| June 13, 2026 | Source | New source added: FDA Grants Accelerated Approval to Pegzilarginase for Arginase 1 Deficiencypharmacytimes.com/view/fda-grants-accelerated-approval-to-pegzilar… | — |
| Pharmacy Times |
| June 13, 2026 | Source | New source added: Arginase 1 deficiency: a treatable form of spastic paraplegiapmc.ncbi.nlm.nih.gov/articles/PMC12394256/ | — |
| June 13, 2026 | Source | New source added: U.S. FDA has granted accelerated approval of Loargys (pegzilarginase-nbln) for the treatment of hyperargininemia in patients 2 years and older with Arginase 1 Deficiency (ARG1-D)prnewswire.com/news-releases/us-fda-has-granted-accelerated-app… | — |
| Immedica Pharma via PR Newswire |
| June 13, 2026 | Source | New source added: LOARGYS (pegzilarginase-nbln) injection — DailyMed Prescribing Labeldailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5ceabf2-43a0-4746-937… | — |
| June 13, 2026 | Source | New source added: Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trialpmc.ncbi.nlm.nih.gov/articles/PMC10825663/ | — |
| eClinicalMedicine (The Lancet) |
| June 13, 2026 | Source | New source added: Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulationpmc.ncbi.nlm.nih.gov/articles/PMC12189779/ | — |
| Biomedicines (MDPI) |
| June 13, 2026 | Source | New source added: Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants: A Double-Blind Randomised Controlled Studypmc.ncbi.nlm.nih.gov/articles/PMC10892859/ | — |
| Nutrients (MDPI) |
| June 13, 2026 | Source | New source added: Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potentialpmc.ncbi.nlm.nih.gov/articles/PMC5332261/ | — |
| Food Science and Nutrition |
| June 13, 2026 | Source | New source added: Palmitoylethanolamide: A Natural Compound for Health Managementpmc.ncbi.nlm.nih.gov/articles/PMC8157570/ | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanismpmc.ncbi.nlm.nih.gov/articles/PMC3596927/ | — |
| Mediators of Inflammation |
| June 13, 2026 | Source | New source added: Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trialpubmed.ncbi.nlm.nih.gov/27227691/ | — |
| Pain |
| June 13, 2026 | Source | New source added: A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic painpmc.ncbi.nlm.nih.gov/articles/PMC9700575/ | — |
| Pain and Therapy |
| June 13, 2026 | Source | New source added: Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trialspmc.ncbi.nlm.nih.gov/articles/PMC10053226/ | — |
| Nutrients (MDPI) |
| June 13, 2026 | Source | New source added: Syn-Coll (Palmitoyl Tripeptide-5) — Active Ingredient Safety Datarootsbybenda.com/ingredients/syn-coll-palmitoyl-tripeptide-5 | — |
| Roots by Benda |
| June 13, 2026 | Source | New source added: Palmitoyl Tripeptide-5 (Explained + Products)incidecoder.com/ingredients/palmitoyl-tripeptide-5 | — |
| INCIDecoder |
| June 13, 2026 | Source | New source added: Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmeticscir-safety.org/sites/default/files/palmit072012slr.pdf | — |
| Cosmetic Ingredient Review (CIR) |
| June 13, 2026 | Source | New source added: Function of Palmitoyl Tripeptide-5creative-peptides.com/article/palmitoyl-tripeptide-5-148.html | — |
| Creative Peptides |
| June 13, 2026 | Source | New source added: Activation of latent transforming growth factor-beta by thrombospondin-1: mechanisms and physiologycorepeptides.com/palmitoyl-tripeptide-5-syn-coll-peptide-research… | — |
| Core Peptides (cites Murphy-Ullrich & Poczatek 2000, DOI 10.1016/s1359-6101(99)00029-5) |
| June 13, 2026 | Source | New source added: Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinklesjcadonline.com/immediate-and-long-term-clinical-benefits-of-a-t… | — |
| Journal of Clinical and Aesthetic Dermatology |
| June 13, 2026 | Source | New source added: Role of topical peptides in preventing or treating aged skinpubmed.ncbi.nlm.nih.gov/19570099/ | — |
| International Journal of Cosmetic Science |
| June 13, 2026 | Source | New source added: Palmitoyl tripeptide-5 — Compound Summary (CID 11950477)pubchem.ncbi.nlm.nih.gov/compound/Palmitoyl-Tripeptide-5 | — |
| National Center for Biotechnology Information (NCBI) |
| June 13, 2026 | Source | New source added: Peptide 021 - Wikipediaen.wikipedia.org/wiki/Peptide_021 | — |
| June 13, 2026 | Source | New source added: Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's diseasepmc.ncbi.nlm.nih.gov/articles/PMC12993872/ | — |
| Magnetic Resonance Imaging / Elsevier |
| June 13, 2026 | Source | New source added: Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorderpmc.ncbi.nlm.nih.gov/articles/PMC11590213/ | — |
| Journal of Neurodevelopmental Disorders |
| June 13, 2026 | Source | New source added: Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndromepmc.ncbi.nlm.nih.gov/articles/PMC5377379/ | — |
| Scientific Reports / Nature Publishing Group |
| June 13, 2026 | Source | New source added: Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compoundpmc.ncbi.nlm.nih.gov/articles/PMC5488423/ | — |
| Alzheimer's Research & Therapy / BioMed Central |
| June 13, 2026 | Source | New source added: Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's diseasepmc.ncbi.nlm.nih.gov/articles/PMC4940708/ | — |
| Molecular Neurodegeneration / BioMed Central |
| June 13, 2026 | Source | New source added: Beneficial Effect of a CNTF Tetrapeptide on Adult Hippocampal Neurogenesis, Neuronal Plasticity, and Spatial Memory in Micepubmed.ncbi.nlm.nih.gov/20952820/ | — |
| Journal of Alzheimer's Disease / IOS Press |
| June 13, 2026 | Source | New source added: Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in micefebs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2010.06.025 | — |
| FEBS Letters / Wiley |
| June 13, 2026 | Source | New source added: Semax - Wikipediaen.wikipedia.org/wiki/Semax | — |
| June 13, 2026 | Source | New source added: [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]pubmed.ncbi.nlm.nih.gov/15792140/ | — |
| Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova |
| June 13, 2026 | Source | New source added: [Effectiveness of semax in acute period of hemispheric ischemic stroke]pubmed.ncbi.nlm.nih.gov/11517472/ | — |
| Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova |
| June 13, 2026 | Source | New source added: Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stresspubmed.ncbi.nlm.nih.gov/39442746/ | — |
| European Journal of Pharmacology |
| June 13, 2026 | Source | New source added: The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Diseasepmc.ncbi.nlm.nih.gov/articles/PMC12755871/ | — |
| Acta Naturae |
| June 13, 2026 | Source | New source added: Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusionpmc.ncbi.nlm.nih.gov/articles/PMC8226508/ | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Ratspmc.ncbi.nlm.nih.gov/articles/PMC7350263/ | — |
| Genes (MDPI) |
| June 13, 2026 | Source | New source added: Semax, An ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodentspubmed.ncbi.nlm.nih.gov/16362768/ | — |
| Neurochemical Research |
| June 13, 2026 | Source | New source added: Semax — Cognitive Vitality For Researchersalzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive… | — |
| Alzheimer's Drug Discovery Foundation |
| June 13, 2026 | Source | New source added: Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Ratspmc.ncbi.nlm.nih.gov/articles/PMC7350263/ | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: The efficacy of semax in the treatment of patients at different stages of ischemic strokepubmed.ncbi.nlm.nih.gov/29798983/ | — |
| June 13, 2026 | Source | New source added: Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemiapmc.ncbi.nlm.nih.gov/articles/PMC11498467/ | — |
| Cellular and Molecular Neurobiology |
| June 13, 2026 | Source | New source added: Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusionpmc.ncbi.nlm.nih.gov/articles/PMC8226508/ | — |
| International Journal of Molecular Sciences |
| June 13, 2026 | Source | New source added: Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodentspubmed.ncbi.nlm.nih.gov/16362768/ | — |
| Neurochemical Research |
| June 13, 2026 | Source | New source added: Effects of Semax on the Default Mode Network of the Brainpubmed.ncbi.nlm.nih.gov/30225715/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampuspubmed.ncbi.nlm.nih.gov/16996037/ | — |
| Brain Research |
| June 13, 2026 | Source | New source added: N-Acetyl Selank Amidate: Reviews, Clinical Studies, and Safetypeptides.org/n-acetyl-selank-amidate/ | — |
| Peptides.org |
| June 13, 2026 | Source | New source added: Selank — Wikipediaen.wikipedia.org/wiki/Selank | — |
| Wikimedia Foundation |
| June 13, 2026 | Source | New source added: GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cellsfrontiersin.org/journals/pharmacology/articles/10.3389/fphar.201… | — |
| Frontiers in Pharmacology |
| June 13, 2026 | Source | New source added: Immunomodulatory effects of selank in patients with anxiety-asthenic disorderspubmed.ncbi.nlm.nih.gov/18577961/ | — |
| Zh Nevrol Psikhiatr Im S S Korsakova |
| June 13, 2026 | Source | New source added: The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activitypubmed.ncbi.nlm.nih.gov/11550013/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Ratspmc.ncbi.nlm.nih.gov/articles/PMC5322660/ | — |
| Behavioural Neurology |
| June 13, 2026 | Source | New source added: Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmissionpmc.ncbi.nlm.nih.gov/articles/PMC4757669/ | — |
| Frontiers in Pharmacology |
| June 13, 2026 | Source | New source added: Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activitypubmed.ncbi.nlm.nih.gov/30255741/ | — |
| June 13, 2026 | Source | New source added: GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cellspmc.ncbi.nlm.nih.gov/articles/PMC5328971/ | — |
| June 13, 2026 | Source | New source added: Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment in Rodentspubmed.ncbi.nlm.nih.gov/31625062/ | — |
| June 13, 2026 | Source | New source added: Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmissionpmc.ncbi.nlm.nih.gov/articles/PMC4757669/ | — |
| June 13, 2026 | Source | New source added: [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]pubmed.ncbi.nlm.nih.gov/18577961/ | — |
| Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova |
| June 13, 2026 | Source | New source added: The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activitypubmed.ncbi.nlm.nih.gov/11550013/ | — |
| June 13, 2026 | Source | New source added: Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Ratspmc.ncbi.nlm.nih.gov/articles/PMC5322660/ | — |
| Behavioural Neurology (Wiley) |
| June 13, 2026 | Source | New source added: [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]pubmed.ncbi.nlm.nih.gov/18454096/ | — |
| Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova |
| June 13, 2026 | Source | New source added: The protective role of ginsenoside Rg3 in heart diseases and mental disordersfrontiersin.org/journals/pharmacology/articles/10.3389/fphar.202… | — |
| Frontiers in Pharmacology |
| June 13, 2026 | Source | New source added: The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trialspmc.ncbi.nlm.nih.gov/articles/PMC8012535/ | — |
| Frontiers in Pharmacology |
| June 13, 2026 | Source | New source added: Acute and repeated dose 26-week oral toxicity study of 20(S)-ginsenoside Rg3 in Kunming mice and Sprague-Dawley ratspmc.ncbi.nlm.nih.gov/articles/PMC7031733/ | — |
| June 13, 2026 | Source | New source added: Ginsenoside Rg3 Prevents Cognitive Impairment by Improving Mitochondrial Dysfunction in the Rat Model of Alzheimer's Diseasepubmed.ncbi.nlm.nih.gov/31422666/ | — |
| Journal of Agricultural and Food Chemistry |
| June 13, 2026 | Source | New source added: Active ginseng components in cognitive impairment: Therapeutic potential and prospects for delivery and clinical studypmc.ncbi.nlm.nih.gov/articles/PMC6173364/ | — |
| Oncotarget |
| June 13, 2026 | Source | New source added: Rg3-enriched ginseng extract ameliorates scopolamine-induced learning deficits in micepmc.ncbi.nlm.nih.gov/articles/PMC4758096/ | — |
| BMC Complementary and Alternative Medicine |
| June 13, 2026 | Source | New source added: Ginseng ginsenoside pharmacology in the nervous system: involvement in the regulation of ion channels and receptorspmc.ncbi.nlm.nih.gov/articles/PMC3958645/ | — |
| Frontiers in Physiology |
| June 13, 2026 | Source | New source added: Ginsenoside Rg3 antagonizes NMDA receptors through a glycine modulatory site in rat cultured hippocampal neuronspubmed.ncbi.nlm.nih.gov/15369768/ | — |
| Biochemical and Biophysical Research Communications |
| June 13, 2026 | Source | New source added: FDA Approves New Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Womenprnewswire.com/news-releases/fda-approves-new-treatment-for-hyp… | — |
| PR Newswire / AMAG Pharmaceuticals |
| June 13, 2026 | Source | New source added: Vyleesi (Bremelanotide Injection) — Official Patient Sitevyleesi.com | — |
| AMAG Pharmaceuticals |
| June 13, 2026 | Source | New source added: The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Resultspubmed.ncbi.nlm.nih.gov/33538638/ | — |
| Journal of Women's Health |
| June 13, 2026 | Source | New source added: Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorderpmc.ncbi.nlm.nih.gov/articles/PMC8788464/ | — |
| PubMed Central |
| June 13, 2026 | Source | New source added: Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trialspubmed.ncbi.nlm.nih.gov/31599840/ | — |
| Obstetrics & Gynecology |
| June 13, 2026 | Source | New source added: FDA Approves New Drug Application for Vyleesi (bremelanotide injection)palatin.com/press_releases/fda-approves-new-drug-application… | — |
| Palatin Technologies |
| June 13, 2026 | Source | New source added: Bremelanotide for Treatment of Female Hypoactive Sexual Desirepmc.ncbi.nlm.nih.gov/articles/PMC8788464/ | — |
| June 13, 2026 | Source | New source added: Bremelanotide - LiverTox: Clinical and Research Information on Drug-Induced Liver Injuryncbi.nlm.nih.gov/books/NBK573221/ | — |
| National Library of Medicine (NIH NCBI Bookshelf) |
| June 13, 2026 | Source | New source added: The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Resultspubmed.ncbi.nlm.nih.gov/33538638/ | — |
| June 13, 2026 | Source | New source added: Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotidepubmed.ncbi.nlm.nih.gov/31277966/ | — |
| June 13, 2026 | Source | New source added: Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotidepubmed.ncbi.nlm.nih.gov/35230162/ | — |
| June 13, 2026 | Source | New source added: Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trialspubmed.ncbi.nlm.nih.gov/31599840/ | — |
| Obstetrics & Gynecology |
| June 13, 2026 | Source | New source added: Prostatilen (Prostate Extract - Prostatilenum) 50 mg, 10 suppositories — product listingrxeli.com/product/prostatilen-prostate-extract-prostatilen… | — |
| June 13, 2026 | Source | New source added: Our experience in the use of prostatilen in urologypubmed.ncbi.nlm.nih.gov/14708243/ | — |
| June 13, 2026 | Source | New source added: The use of prostatilen in treating patients with prostatic adenomapubmed.ncbi.nlm.nih.gov/1823683/ | — |
| June 13, 2026 | Source | New source added: Polypeptide prostatilen in the treatment of patients with complicated prostatitispubmed.ncbi.nlm.nih.gov/15605829/ | — |
| June 13, 2026 | Source | New source added: Effect of prostatilen AC suppositories on course of experimental prostatitispubmed.ncbi.nlm.nih.gov/23116023/ | — |
| June 13, 2026 | Source | New source added: Influence of adding zinc arginyle-glycinate to improve efficacy of bioregulatory peptides of the prostate gland in treatment of patients with impaired sperm parameterspubmed.ncbi.nlm.nih.gov/36318852/ | — |
| June 13, 2026 | Source | New source added: Bioregulatory therapy for chronic abacterial prostatitisjournals.eco-vector.com/uroved/article/view/111581 | — |
| Urology Reports (St. Petersburg), Eco-Vector |
| June 13, 2026 | Source | New source added: Prostatic bioregulatory polypeptide prostatilen: pharmacological properties and 30-year experience of clinical application in urologyjournals.eco-vector.com/uroved/article/view/42472 | — |
| Urology Reports (St. Petersburg), Eco-Vector |
| June 13, 2026 | Source | New source added: Pramlintide - Wikidocwikidoc.org/index.php/Pramlintide | — |
| June 13, 2026 | Source | New source added: Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetesacademic.oup.com/jcemcr/article/1/2/luad040/7135533 | — |
| JCEM Case Reports / The Endocrine Society |
| June 13, 2026 | Source | New source added: Primer on pramlintide, an amylin analogpubmed.ncbi.nlm.nih.gov/21471470/ | — |
| June 13, 2026 | Source | New source added: Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patientspubmed.ncbi.nlm.nih.gov/15090634/ | — |
| Obesity Research |
| June 13, 2026 | Source | New source added: Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targetspubmed.ncbi.nlm.nih.gov/14617226/ | — |
| June 13, 2026 | Source | New source added: The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysispubmed.ncbi.nlm.nih.gov/21199269/ | — |
| Diabetes, Obesity and Metabolism |
| June 13, 2026 | Source | New source added: Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysispmc.ncbi.nlm.nih.gov/articles/PMC5630431/ | — |
| June 13, 2026 | Source | New source added: Pinealon — Wikipediaen.wikipedia.org/wiki/Pinealon | — |
| Wikimedia Foundation |
| June 13, 2026 | Source | New source added: Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Diseasepubmed.ncbi.nlm.nih.gov/28853087/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Pinealon protects the rat offspring from prenatal hyperhomocysteinemiapubmed.ncbi.nlm.nih.gov/22567179/ | — |
| International Journal of Clinical and Experimental Medicine |
| June 13, 2026 | Source | New source added: Neuroprotective Effects of Tripeptides — Epigenetic Regulators in Mouse Model of Alzheimer's Diseasepmc.ncbi.nlm.nih.gov/articles/PMC8227791/ | — |
| MDPI Pharmaceuticals |
| June 13, 2026 | Source | New source added: EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Diseasepmc.ncbi.nlm.nih.gov/articles/PMC7795577/ | — |
| MDPI Molecules |
| June 13, 2026 | Source | New source added: N-Acetyl Semax Amidate: Research Evidence and Safety Profilepeptideinsight.com/en/peptides/n-acetyl-semax-amidate | — |
| PeptideInsight |
| June 13, 2026 | Source | New source added: Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Modelspmc.ncbi.nlm.nih.gov/articles/PMC8855339/ | — |
| ACS Chemical Neuroscience |
| June 13, 2026 | Source | New source added: Effects of Semax on the Default Mode Network of the Brainpubmed.ncbi.nlm.nih.gov/30225715/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 13, 2026 | Source | New source added: Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemiapmc.ncbi.nlm.nih.gov/articles/PMC11498467/ | — |
| Cellular and Molecular Neurobiology |
| June 13, 2026 | Source | New source added: Effects of behaviorally active ACTH(4-10) analogue Semax on rat basal forebrain cholinergic neuronspubmed.ncbi.nlm.nih.gov/18431004/ | — |
| Restorative Neurology and Neuroscience |
| June 13, 2026 | Source | New source added: Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodentspubmed.ncbi.nlm.nih.gov/16362768/ | — |
| Neurochemical Research |
| June 13, 2026 | Source | New source added: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampuspubmed.ncbi.nlm.nih.gov/16996037/ | — |
| Brain Research |
| June 13, 2026 | Source | New source added: Semax - Wikipediaen.wikipedia.org/wiki/Semax | — |
| Wikimedia Foundation |
| June 12, 2026 | Source | New source added: Metreleptin (Myalept) - Medical Clinical Policy Bulletinaetna.com/cpb/medical/data/800_899/0882.html | — |
| Aetna |
| June 12, 2026 | Source | New source added: Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studiespnas.org/doi/10.1073/pnas.0706473105 | — |
| Proceedings of the National Academy of Sciences |
| June 12, 2026 | Source | New source added: Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophypubmed.ncbi.nlm.nih.gov/26465174/ | — |
| June 12, 2026 | Source | New source added: Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiencyjci.org/articles/view/15693 | — |
| Journal of Clinical Investigation |
| June 12, 2026 | Source | New source added: Structural insights into the mechanism of leptin receptor activationpmc.ncbi.nlm.nih.gov/articles/PMC10066393/ | — |
| Nature Communications |
| June 12, 2026 | Source | New source added: New advances in the treatment of generalized lipodystrophy: role of metreleptinpmc.ncbi.nlm.nih.gov/articles/PMC4577254/ | — |
| June 12, 2026 | Source | New source added: Recent advances in understanding leptin signaling and leptin resistancepmc.ncbi.nlm.nih.gov/articles/PMC2793049/ | — |
| American Journal of Physiology |
| June 12, 2026 | Source | New source added: Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms (CedLara)clinicaltrials.gov/study/NCT03569007 | — |
| ClinicalTrials.gov |
| June 12, 2026 | Source | New source added: Clinical Trial Finds Safe, Effective Treatment for Children with Severe Post-COVID Syndromemassgeneralbrigham.org/en/about/newsroom/press-releases/clinical-trial-… | — |
| Mass General Brigham |
| June 12, 2026 | Source | New source added: A systematic review and meta-analysis of randomized controlled trials: Efficacy and safety of larazotide acetate in celiac disease patients undergoing a gluten challengesymbiosisonlinepublishing.com/gastroenterology-pancreatology-liverdisorders/ga… | — |
| June 12, 2026 | Source | New source added: Larazotide acetate: a pharmacological peptide approach to tight junction regulationpmc.ncbi.nlm.nih.gov/articles/PMC11735010/ | — |
| American Journal of Physiology-Gastrointestinal and Liver Physiology |
| June 12, 2026 | Source | New source added: The potential utility of tight junction regulation in celiac disease: focus on larazotide acetatepubmed.ncbi.nlm.nih.gov/26770266/ | — |
| Therapeutic Advances in Gastroenterology |
| June 12, 2026 | Source | New source added: A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challengepubmed.ncbi.nlm.nih.gov/22825365/ | — |
| June 12, 2026 | Source | New source added: Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled studypubmed.ncbi.nlm.nih.gov/23163616/ | — |
| Gut |
| June 12, 2026 | Source | New source added: Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trialpubmed.ncbi.nlm.nih.gov/25683116/ | — |
| Gastroenterology |
| June 12, 2026 | Source | New source added: KPV tripeptide — Wikipediaen.wikipedia.org/wiki/KPV_tripeptide | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathwaypubmed.ncbi.nlm.nih.gov/40073467/ | — |
| Tissue and Cell (Elsevier) |
| June 12, 2026 | Source | New source added: The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentialspubmed.ncbi.nlm.nih.gov/37508552/ | — |
| Cells (MDPI) |
| June 12, 2026 | Source | New source added: Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonistsdiscovery.dundee.ac.uk/en/publications/inhibition-of-cellular-and-syste… | — |
| International Journal of Physiology, Pathophysiology and Pharmacology |
| June 12, 2026 | Source | New source added: Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophorepubmed.ncbi.nlm.nih.gov/21222263/ | — |
| Advances in Experimental Medicine and Biology (Springer) |
| June 12, 2026 | Source | New source added: Antimicrobial effects of alpha-MSH peptidespubmed.ncbi.nlm.nih.gov/10670585/ | — |
| Journal of Leukocyte Biology |
| June 12, 2026 | Source | New source added: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationpubmed.ncbi.nlm.nih.gov/18061177/ | — |
| Gastroenterology (Elsevier) |
| June 12, 2026 | Source | New source added: Emerging Therapeutic Potential of Kisspeptin and Neurokinin Bacademic.oup.com/edrv/article/45/1/30/7226658 | — |
| Endocrine Reviews |
| June 12, 2026 | Source | New source added: Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humanspmc.ncbi.nlm.nih.gov/articles/PMC12018048/ | — |
| June 12, 2026 | Source | New source added: Increasing LH Pulsatility in Women With Hypothalamic Amenorrhoea Using Intravenous Infusion of Kisspeptin-54pmc.ncbi.nlm.nih.gov/articles/PMC4207927/ | — |
| June 12, 2026 | Source | New source added: Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapypmc.ncbi.nlm.nih.gov/articles/PMC4570165/ | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilizationjci.org/articles/view/75730 | — |
| Journal of Clinical Investigation |
| June 12, 2026 | Source | New source added: The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproductionpmc.ncbi.nlm.nih.gov/articles/PMC9273750/ | — |
| June 12, 2026 | Source | New source added: IMUNOFAN — Official Manufacturer Information (NPP BIONOX)imunofan.ru/en/main/ | — |
| NPP BIONOX, Russia |
| June 12, 2026 | Source | New source added: [The immunocorrective action of the new synthetic hexapeptide imunofan in pharmacologically induced and ecological immunodeficiency]pubmed.ncbi.nlm.nih.gov/8664598/ | — |
| Vestnik Rossiiskoi Akademii Meditsinskikh Nauk |
| June 12, 2026 | Source | New source added: P20 - The use of regulatory hexapeptide on frequently ill childrenpmc.ncbi.nlm.nih.gov/articles/PMC4081846/ | — |
| BMC Infectious Diseases (conference supplement) |
| June 12, 2026 | Source | New source added: Role of immunotherapy in complex treatment of acute optic neuritis associated with herpesvirus infectionactabiomedica.ru/jour/article/view/3439/0?locale=en_US | — |
| Acta Biomedica Scientifica |
| June 12, 2026 | Source | New source added: [Experimental study of the effectiveness of the use of imunofan in the treatment of viral diseases of the eye]pubmed.ncbi.nlm.nih.gov/11765469/ | — |
| June 12, 2026 | Source | New source added: Hydrophilic hexapeptide Imunofan as a hyperactive regulator of transport proteins for multiple drug resistancepubmed.ncbi.nlm.nih.gov/17603672/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: [A trial of the use of the immunocorrective preparation Imunofan for treating diphtheria]pubmed.ncbi.nlm.nih.gov/8771665/ | — |
| Terapevticheskii Arkhiv |
| June 12, 2026 | Source | New source added: Imunofan—RDKVYR Peptide—Stimulates Skin Cell Proliferation and Promotes Tissue Repairpmc.ncbi.nlm.nih.gov/articles/PMC7355430/ | — |
| MDPI Molecules |
| June 12, 2026 | Source | New source added: Ovagen Peptide: Liver Health, Cellular and Gastrointestinal Bioregulatorjaycampbell.com/peptides/ovagen-peptide/ | — |
| JayCampbell.com |
| June 12, 2026 | Source | New source added: Buy OVAGEN (liver peptides) - product pagecosmicnootropic.com/products/ovagen-bioregulator/ | — |
| CosmicNootropic |
| June 12, 2026 | Source | New source added: Ovagen - Liver and Gastrointestinal Tract Bioregulator (product information)antiaging-systems.com/products/liver-and-gastrointestinal-tract-bioreg… | — |
| Antiaging Systems |
| June 12, 2026 | Source | New source added: Vladimir Khavinson - Wikipediaen.wikipedia.org/wiki/Vladimir_Khavinson | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathologypubmed.ncbi.nlm.nih.gov/32362099/ | — |
| Advances in Gerontology |
| June 12, 2026 | Source | New source added: Tripeptides slow down aging process in renal cell culturepubmed.ncbi.nlm.nih.gov/25946838/ | — |
| Advances in Gerontology |
| June 12, 2026 | Source | New source added: Short Peptides Regulate Gene Expressionpubmed.ncbi.nlm.nih.gov/27909961/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: ATTAIN-Outcomes: Cardiovascular Outcomes Study of Orforglipron (NCT07241390)clinicaltrials.gov/study/NCT07241390 | — |
| ClinicalTrials.gov / Eli Lilly |
| June 12, 2026 | Source | New source added: Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes — PMCpmc.ncbi.nlm.nih.gov/articles/PMC12898445/ | — |
| International Journal of Molecular Sciences / PMC |
| June 12, 2026 | Source | New source added: Orforglipron (LY3502970): Phase 1b Multiple-Ascending-Dose Study in Type 2 Diabetespubmed.ncbi.nlm.nih.gov/37264711/ | — |
| June 12, 2026 | Source | New source added: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes — ACHIEVE-1 Phase 3nejm.org/doi/full/10.1056/NEJMoa2505669 | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity in people with type 2 diabetes (ATTAIN-2) — The Lancetthelancet.com/journals/lancet/article/PIIS0140-6736(25)02165-8… | — |
| The Lancet |
| June 12, 2026 | Source | New source added: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for Obesity Treatment — ATTAIN-1 Phase 3nejm.org/doi/full/10.1056/NEJMoa2511774 | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (Phase 2)nejm.org/doi/full/10.1056/NEJMoa2302392 | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: FOUNDAYO (orforglipron) tablets — DailyMed FDA Prescribing Information (NDA 220934)dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a… | — |
| U.S. National Library of Medicine / FDA |
| June 12, 2026 | Source | New source added: Antidepressant with novel action appears safe and effective in phase 1b clinical trialeurekalert.org/news-releases/628798 | — |
| EurekAlert / AAAS |
| June 12, 2026 | Source | New source added: Study of NSI-189 Phosphate for Major Depressive Disorder (NCT02695472)clinicaltrials.gov/study/NCT02695472 | — |
| June 12, 2026 | Source | New source added: Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorderglobenewswire.com/news-release/2017/07/25/1057673/0/en/Neuralstem-… | — |
| June 12, 2026 | Source | New source added: Amelioration of Both Central and Peripheral Neuropathy in Mouse Models of Type 1 and Type 2 Diabetes by the Neurogenic Molecule NSI-189pmc.ncbi.nlm.nih.gov/articles/PMC6804627/ | — |
| Diabetes (American Diabetes Association) |
| June 12, 2026 | Source | New source added: Enhancement of synaptic plasticity and reversal of impairments in motor and cognitive functions in a mouse model of Angelman Syndrome by a small neurogenic molecule, NSI-189pubmed.ncbi.nlm.nih.gov/30408487/ | — |
| Neuropharmacology |
| June 12, 2026 | Source | New source added: A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patientspubmed.ncbi.nlm.nih.gov/27528461/ | — |
| Molecular Psychiatry |
| June 12, 2026 | Source | New source added: A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorderpmc.ncbi.nlm.nih.gov/articles/PMC7303010/ | — |
| Molecular Psychiatry |
| June 12, 2026 | Source | New source added: FDA declares NMN lawful in dietary supplementsnutraingredients.com/Article/2025/09/30/fda-declares-nmn-lawful-in-di… | — |
| NutraIngredients |
| June 12, 2026 | Source | New source added: The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysispmc.ncbi.nlm.nih.gov/articles/PMC12022230/ | — |
| Journal of Cachexia, Sarcopenia and Muscle |
| June 12, 2026 | Source | New source added: Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trialspmc.ncbi.nlm.nih.gov/articles/PMC11365583/ | — |
| Journal of Nutrition and Metabolism |
| June 12, 2026 | Source | New source added: Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Moleculepmc.ncbi.nlm.nih.gov/articles/PMC6359187/ | — |
| Molecules |
| June 12, 2026 | Source | New source added: Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjectspmc.ncbi.nlm.nih.gov/articles/PMC9036060/ | — |
| Frontiers in Nutrition |
| June 12, 2026 | Source | New source added: The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trialpmc.ncbi.nlm.nih.gov/articles/PMC9735188/ | — |
| GeroScience |
| June 12, 2026 | Source | New source added: The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Updatepmc.ncbi.nlm.nih.gov/articles/PMC10721522/ | — |
| Frontiers in Nutrition |
| June 12, 2026 | Source | New source added: FDA declares NMN lawful in dietary supplementsnutraingredients.com/Article/2025/09/30/fda-declares-nmn-lawful-in-di… | — |
| NutraIngredients |
| June 12, 2026 | Source | New source added: The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysispmc.ncbi.nlm.nih.gov/articles/PMC12022230/ | — |
| Journal of Cachexia, Sarcopenia and Muscle |
| June 12, 2026 | Source | New source added: Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trialspmc.ncbi.nlm.nih.gov/articles/PMC11365583/ | — |
| Journal of Nutrition and Metabolism |
| June 12, 2026 | Source | New source added: Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Moleculepmc.ncbi.nlm.nih.gov/articles/PMC6359187/ | — |
| Molecules |
| June 12, 2026 | Source | New source added: Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjectspmc.ncbi.nlm.nih.gov/articles/PMC9036060/ | — |
| Frontiers in Nutrition |
| June 12, 2026 | Source | New source added: The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trialpmc.ncbi.nlm.nih.gov/articles/PMC9735188/ | — |
| GeroScience |
| June 12, 2026 | Source | New source added: The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Updatepmc.ncbi.nlm.nih.gov/articles/PMC10721522/ | — |
| Frontiers in Nutrition |
| June 12, 2026 | Source | New source added: Navepegritide: Uses, Interactions, Mechanism of Action — DrugBankgo.drugbank.com/drugs/DB17824 | — |
| June 12, 2026 | Source | New source added: FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older — Ascendis Pharma Press Releaseinvestors.ascendispharma.com/news-releases/news-release-details/fda-approves-… | — |
| Ascendis Pharma |
| June 12, 2026 | Source | New source added: New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon hGH Accelerated TransCon CNP's Benefits Beyond Linear Growth in Children with Achondroplasiaglobenewswire.com/news-release/2026/04/08/3270080/0/en/New-Data-fr… | — |
| Ascendis Pharma / GlobeNewswire |
| June 12, 2026 | Source | New source added: Molecular Mechanism of Induction of Bone Growth by the C-Type Natriuretic Peptidepmc.ncbi.nlm.nih.gov/articles/PMC9180634/ | — |
| June 12, 2026 | Source | New source added: Navepegritide (Yuviwel) for Children with Achondroplasia: New Drugs and Therapeutics — Pediatric Endocrine Societypedsendo.org/new-meds-and-tech/navepegritide-yuviwel-for-chil… | — |
| June 12, 2026 | Source | New source added: YUVIWEL (navepegritide) Prescribing Information — DailyMeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e01c1197-338f-414c-b… | — |
| June 12, 2026 | Source | New source added: Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trialpmc.ncbi.nlm.nih.gov/articles/PMC12624480/ | — |
| JAMA Pediatrics / PubMed Central |
| June 12, 2026 | Source | New source added: Gonadorelin — Wikipediaen.wikipedia.org/wiki/Gonadorelin | — |
| Wikimedia Foundation |
| June 12, 2026 | Source | New source added: Gonadotropin Releasing Hormone (GnRH) Analogues — LiverTox: Clinical and Research Information on Drug-Induced Liver Injuryncbi.nlm.nih.gov/books/NBK547863/ | — |
| National Institute of Diabetes and Digestive and Kidney Diseases / NCBI Bookshelf |
| June 12, 2026 | Source | New source added: Factrel (Gonadorelin Hydrochloride): Full Prescribing Information — RxListrxlist.com/factrel-drug.htm | — |
| RxList / WebMD |
| June 12, 2026 | Source | New source added: Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective studypmc.ncbi.nlm.nih.gov/articles/PMC12336735/ | — |
| Translational Andrology and Urology |
| June 12, 2026 | Source | New source added: Spermatogenesis of Male Patients with Congenital Hypogonadotropic Hypogonadism Receiving Pulsatile Gonadotropin-Releasing Hormone Therapy Versus Gonadotropin Therapy: A Systematic Review and Meta-Analysispmc.ncbi.nlm.nih.gov/articles/PMC8443979/ | — |
| World Journal of Men's Health |
| June 12, 2026 | Source | New source added: Use of pulsatile gonadotropin-releasing hormone (GnRH) in patients with functional hypothalamic amenorrhea (FHA) results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohortpmc.ncbi.nlm.nih.gov/articles/PMC9790838/ | — |
| Journal of Assisted Reproduction and Genetics |
| June 12, 2026 | Source | New source added: Glycine's Role In Sleep Enhancement: Clinical Evidence, Mechanisms, and Therapeutic Applicationsglobalrph.com/2025/10/glycines-role-in-sleep-enhancement-clini… | — |
| GlobalRPH |
| June 12, 2026 | Source | New source added: Glycine: Health Benefits, Side Effects, Uses, Dose & Precautionsrxlist.com/supplements/glycine.htm | — |
| RxList |
| June 12, 2026 | Source | New source added: Glycine for Sleepsleepfoundation.org/sleep-aids/glycine-for-sleep | — |
| Sleep Foundation |
| June 12, 2026 | Source | New source added: Glycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changesonlinelibrary.wiley.com/doi/10.1111/j.1479-8425.2007.00262.x | — |
| Sleep and Biological Rhythms (Wiley) |
| June 12, 2026 | Source | New source added: Collagen peptide supplementation before bedtime reduces sleep fragmentation and improves cognitive function in physically active males with sleep complaintspmc.ncbi.nlm.nih.gov/articles/PMC10799148/ | — |
| British Journal of Nutrition |
| June 12, 2026 | Source | New source added: The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleuspubmed.ncbi.nlm.nih.gov/25533534/ | — |
| Neuropsychopharmacology |
| June 12, 2026 | Source | New source added: The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteerspubmed.ncbi.nlm.nih.gov/22529837/ | — |
| Frontiers in Neurology |
| June 12, 2026 | Source | New source added: Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cellspubmed.ncbi.nlm.nih.gov/35783198/ | — |
| Drug Design, Development and Therapy |
| June 12, 2026 | Source | New source added: Metabolic Pharmaceuticals AOD9604 Phase 2B Trial Updatebiospace.com/metabolic-pharmaceuticals-s-obesity-trial-update… | — |
| BioSpace |
| June 12, 2026 | Source | New source added: Obesity drug codenamed AOD9604 highly successful in trials (Phase IIa results)news-medical.net/news/2004/12/16/6878.aspx | — |
| News-Medical.Net |
| June 12, 2026 | Source | New source added: AOD9604 — Wikipediaen.wikipedia.org/wiki/AOD9604 | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: HGH Fragment 176-191 — Wikipediaen.wikipedia.org/wiki/HGH_Fragment_176%E2%80%93191 | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: Safety and Tolerability of the Hexadecapeptide AOD9604 in Humansjofem.org/index.php/jofem/article/view/157/194 | — |
| Journal of Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out micepubmed.ncbi.nlm.nih.gov/11713213/ | — |
| Endocrinology (Oxford Academic) |
| June 12, 2026 | Source | New source added: Peptide Sparks Synaptic Plasticity, Improves Memory in Rodentsalzforum.org/news/research-news/peptide-sparks-synaptic-plast… | — |
| Alzforum |
| June 12, 2026 | Source | New source added: The neural cell adhesion molecule-derived peptide FGL facilitates long-term plasticity in the dentate gyrus in vivolearnmem.cshlp.org/content/18/5/306.full | — |
| June 12, 2026 | Source | New source added: A neural cell adhesion molecule-derived peptide, FGL, attenuates glial cell activation in the aged hippocampuspubmed.ncbi.nlm.nih.gov/21978973/ | — |
| June 12, 2026 | Source | New source added: Impact of the Neural Cell Adhesion Molecule-Derived Peptide FGL on Seizure Progression and Cellular Alterations in the Mouse Kindling Modelpmc.ncbi.nlm.nih.gov/articles/PMC3963124/ | — |
| June 12, 2026 | Source | New source added: Amyloid-Beta Induced CA1 Pyramidal Cell Loss in Young Adult Rats Is Alleviated by Systemic Treatment with FGL, a Neural Cell Adhesion Molecule-Derived Mimetic Peptidepmc.ncbi.nlm.nih.gov/articles/PMC3739720/ | — |
| June 12, 2026 | Source | New source added: Tolerability, Safety and Pharmacokinetics of the FGLL Peptide, a Novel Mimetic of Neural Cell Adhesion Molecule, Following Intranasal Administration in Healthy Volunteerslink.springer.com/article/10.2165/00003088-200746040-00007 | — |
| Clinical Pharmacokinetics / Springer |
| June 12, 2026 | Source | New source added: Neuritogenic and Neuroprotective Properties of Peptide Agonists of the Fibroblast Growth Factor Receptorpmc.ncbi.nlm.nih.gov/articles/PMC2904917/ | — |
| June 12, 2026 | Source | New source added: A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult both in vitro and in vivopubmed.ncbi.nlm.nih.gov/16197499/ | — |
| June 12, 2026 | Source | New source added: Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational studypmc.ncbi.nlm.nih.gov/articles/PMC5941332/ | — |
| June 12, 2026 | Source | New source added: Effect of once-weekly dulaglutide on renal function in patients with chronic kidney diseasepubmed.ncbi.nlm.nih.gov/35960776/ | — |
| June 12, 2026 | Source | New source added: Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWINDpmc.ncbi.nlm.nih.gov/articles/PMC8466679/ | — |
| June 12, 2026 | Source | New source added: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialsciencedirect.com/science/article/abs/pii/S0140673619311493 | — |
| The Lancet |
| June 12, 2026 | Source | New source added: Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11pubmed.ncbi.nlm.nih.gov/34189841/ | — |
| June 12, 2026 | Source | New source added: Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)diabetesjournals.org/care/article/44/3/765/138650/Efficacy-and-Safety… | — |
| Diabetes Care / American Diabetes Association |
| June 12, 2026 | Source | New source added: Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial programpubmed.ncbi.nlm.nih.gov/27102969/ | — |
| June 12, 2026 | Source | New source added: TRULICITY (dulaglutide) Prescribing Information - DailyMeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af4e38a6-ad3f-480c-a… | — |
| U.S. National Library of Medicine / Eli Lilly and Company |
| June 12, 2026 | Source | New source added: N-Acetyl Semax Amidate Dosage Calculator and Chartpeptides.org/n-acetyl-semax-amidate-dosage-calculator/ | — |
| Peptides.org |
| June 12, 2026 | Source | New source added: N-Acetyl Semax Amidate: Reviews, Clinical Trials, and Safetypeptides.org/n-acetyl-semax-amidate/ | — |
| Peptides.org |
| June 12, 2026 | Source | New source added: Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10 (NCT05648526)clinicaltrials.gov/study/NCT05648526 | — |
| ClinicalTrials.gov |
| June 12, 2026 | Source | New source added: Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusionpmc.ncbi.nlm.nih.gov/articles/PMC8226508/ | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: The efficacy of semax in the treatment of patients at different stages of ischemic strokepubmed.ncbi.nlm.nih.gov/29798983/ | — |
| Zh Nevrol Psikhiatr Im S S Korsakova |
| June 12, 2026 | Source | New source added: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampuspubmed.ncbi.nlm.nih.gov/16996037/ | — |
| Brain Research |
| June 12, 2026 | Source | New source added: MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent mannerpubmed.ncbi.nlm.nih.gov/41520850/ | — |
| Free Radical Biology and Medicine |
| June 12, 2026 | Source | New source added: CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesityglobenewswire.com/news-release/2021/08/10/2278324/0/en/CohBar-Anno… | — |
| GlobeNewswire / CohBar Inc. |
| June 12, 2026 | Source | New source added: MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitationpubmed.ncbi.nlm.nih.gov/36761202/ | — |
| Frontiers in Endocrinology |
| June 12, 2026 | Source | New source added: Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseasese-dmj.org/journal/view.php?number=2725 | — |
| Diabetes and Metabolism Journal |
| June 12, 2026 | Source | New source added: MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseasespmc.ncbi.nlm.nih.gov/articles/PMC9570330/ | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasisnature.com/articles/s41467-020-20790-0 | — |
| Nature Communications |
| June 12, 2026 | Source | New source added: The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stresspubmed.ncbi.nlm.nih.gov/29983246/ | — |
| Cell Metabolism |
| June 12, 2026 | Source | New source added: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistancepubmed.ncbi.nlm.nih.gov/25738459/ | — |
| Cell Metabolism |
| June 12, 2026 | Source | New source added: Growth Hormone Secretagogues as Potential Therapeutic Agents to Restore Growth Hormone Secretion in Older Subjects to Those Observed in Young Adultspmc.ncbi.nlm.nih.gov/articles/PMC10272984/ | — |
| Journals of Gerontology: Series A |
| June 12, 2026 | Source | New source added: Hepatotoxicity induced by MK-677pubmed.ncbi.nlm.nih.gov/40675653/ | — |
| June 12, 2026 | Source | New source added: Could Overt Diabetes Be Triggered by Abuse of Selective Androgen Receptor Modulators and Growth Hormone Secretagogues? A Case Report and Reviewpmc.ncbi.nlm.nih.gov/articles/PMC9331610/ | — |
| Frontiers in Endocrinology |
| June 12, 2026 | Source | New source added: Effects of oral administration of ibutamoren mesylate on the GH-IGF-I axis in GH-deficient children (Codner et al., 2001)pubmed.ncbi.nlm.nih.gov/11452249/ | — |
| Clinical Pharmacology and Therapeutics |
| June 12, 2026 | Source | New source added: Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamorenpmc.ncbi.nlm.nih.gov/articles/PMC8568970/ | — |
| Nature Communications |
| June 12, 2026 | Source | New source added: MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism (Murphy et al., 1998)pubmed.ncbi.nlm.nih.gov/9467534/ | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trialpubmed.ncbi.nlm.nih.gov/19015485/ | — |
| Neurology |
| June 12, 2026 | Source | New source added: Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial (Nass et al., 2008)pmc.ncbi.nlm.nih.gov/articles/PMC2757071/ | — |
| Annals of Internal Medicine |
| June 12, 2026 | Source | New source added: Donepezil and memantine for moderate-to-severe Alzheimer's diseasepubmed.ncbi.nlm.nih.gov/22397651/ | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: DailyMed - MEMANTINE tablet - Full Prescribing Informationdailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5dcc0e7-761f-4294-b… | — |
| National Library of Medicine / DailyMed |
| June 12, 2026 | Source | New source added: Memantine in Psychiatry: An Underutilized Therapeutic Breakthrough?pmc.ncbi.nlm.nih.gov/articles/PMC12260883/ | — |
| June 12, 2026 | Source | New source added: Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer's Diseasepmc.ncbi.nlm.nih.gov/articles/PMC3753463/ | — |
| Neurotoxicity Research / Springer |
| June 12, 2026 | Source | New source added: Memantine Monotherapy for Alzheimer's Disease: A Systematic Review and Meta-Analysisjournals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.012328… | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Basic information about memantine and its treatment of Alzheimer's disease and other clinical applicationspmc.ncbi.nlm.nih.gov/articles/PMC10527776/ | — |
| iBrain / Wiley Online Library |
| June 12, 2026 | Source | New source added: Update on the use of memantine in Alzheimer's diseasepmc.ncbi.nlm.nih.gov/articles/PMC2695219/ | — |
| Neuropsychiatric Disease and Treatment |
| June 12, 2026 | Source | New source added: Memantine - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov/books/NBK500025/ | — |
| StatPearls Publishing / NCBI |
| June 12, 2026 | Source | New source added: Safety of higher doses of melatonin in adults: A systematic review and meta-analysispmc.ncbi.nlm.nih.gov/articles/PMC10109390/ | — |
| Journal of Pineal Research / PMC |
| June 12, 2026 | Source | New source added: A clinical trial with DSIPpubmed.ncbi.nlm.nih.gov/6391926/ | — |
| European Neurology |
| June 12, 2026 | Source | New source added: The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleeppubmed.ncbi.nlm.nih.gov/7028502/ | — |
| Experientia |
| June 12, 2026 | Source | New source added: Delta-sleep-inducing peptide stimulates melatonin, 5-methoxytryptophol and serotonin release from perifused rat pineal glandspubmed.ncbi.nlm.nih.gov/1339175/ | — |
| Biological Signals |
| June 12, 2026 | Source | New source added: Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleeppmc.ncbi.nlm.nih.gov/articles/PMC6407453/ | — |
| Frontiers in Endocrinology |
| June 12, 2026 | Source | New source added: Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trialspubmed.ncbi.nlm.nih.gov/33417003/ | — |
| Journal of Sleep Research |
| June 12, 2026 | Source | New source added: Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorderspmc.ncbi.nlm.nih.gov/articles/PMC3656905/ | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Propertiespmc.ncbi.nlm.nih.gov/articles/PMC11943447/ | — |
| MDPI / PMC |
| June 12, 2026 | Source | New source added: Mitochondrial-derived peptides MOTS-c and humanin attenuate dexamethasone-induced atrophy in human skeletal muscle cellspmc.ncbi.nlm.nih.gov/articles/PMC12930096/ | — |
| June 12, 2026 | Source | New source added: The emerging role of the mitochondrial-derived peptide humanin in stress resistancepubmed.ncbi.nlm.nih.gov/23239898/ | — |
| Journal of Molecular Endocrinology |
| June 12, 2026 | Source | New source added: Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in micepubmed.ncbi.nlm.nih.gov/30004252/ | — |
| June 12, 2026 | Source | New source added: New Role for the Mitochondrial Peptide Humanin: Protective Agent Against Chemotherapy-Induced Side Effectspmc.ncbi.nlm.nih.gov/articles/PMC3982780/ | — |
| Journal of the National Cancer Institute |
| June 12, 2026 | Source | New source added: Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectivespmc.ncbi.nlm.nih.gov/articles/PMC10740898/ | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: The mitochondrial derived peptide humanin is a regulator of lifespan and healthspanaging-us.com/article/103534/text | — |
| Aging (Albany NY) |
| June 12, 2026 | Source | New source added: Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humanspmc.ncbi.nlm.nih.gov/articles/PMC6154958/ | — |
| Scientific Reports (Nature) |
| June 12, 2026 | Source | New source added: Examorelin — Wikipediaen.wikipedia.org/wiki/Examorelin | — |
| June 12, 2026 | Source | New source added: Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicitypmc.ncbi.nlm.nih.gov/articles/PMC8150489/ | — |
| Pharmaceuticals (MDPI) |
| June 12, 2026 | Source | New source added: Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in ratspmc.ncbi.nlm.nih.gov/articles/PMC7018219/ | — |
| June 12, 2026 | Source | New source added: Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarctionpmc.ncbi.nlm.nih.gov/articles/PMC5949285/ | — |
| June 12, 2026 | Source | New source added: Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgerypubmed.ncbi.nlm.nih.gov/12144941/ | — |
| European Journal of Pharmacology |
| June 12, 2026 | Source | New source added: Growth Hormone Status during Long-Term Hexarelin Therapyacademic.oup.com/jcem/article/83/5/1644/2865542 | — |
| Oxford Academic / Endocrine Society |
| June 12, 2026 | Source | New source added: Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response studyacademic.oup.com/jcem/article-abstract/81/12/4338/2650623 | — |
| Oxford Academic / Endocrine Society |
| June 12, 2026 | Source | New source added: Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in manacademic.oup.com/jcem/article-abstract/78/3/693/2651002 | — |
| Oxford Academic / Endocrine Society |
| June 12, 2026 | Source | New source added: What does Hexapeptide-11 do for skin and hair? — ChemicalBookchemicalbook.com/article/what-does-hexapeptide-11-do-for-skin-and… | — |
| June 12, 2026 | Source | New source added: Hexapeptide-11 ingredient listing — INCIDecoderincidecoder.com/ingredients/hexapeptide-11 | — |
| June 12, 2026 | Source | New source added: Peptamide 6 (Hexapeptide-11) — Cosmetic Ingredients Guideci.guide/peptides/peptamidetm-6 | — |
| June 12, 2026 | Source | New source added: Hexapeptide-11 in Skin Care: What It Is and Is It Safe? — Paula's Choicepaulaschoice.de/en/hexapeptide-11/ingredient-hexapeptide-11.html | — |
| June 12, 2026 | Source | New source added: Hexapeptide-11 (CID 24998056) — PubChem Compoundpubchem.ncbi.nlm.nih.gov/compound/Hexapeptide-11 | — |
| National Library of Medicine / NIH |
| June 12, 2026 | Source | New source added: Hexapeptide-11 is a novel modulator of the proteostasis network in human diploid fibroblasts (PMC full text)pmc.ncbi.nlm.nih.gov/articles/PMC4434199/ | — |
| Redox Biology (Elsevier) |
| June 12, 2026 | Source | New source added: Modulation of cellular senescence in fibroblasts and dermal papillae cells in vitropubmed.ncbi.nlm.nih.gov/23578831/ | — |
| Journal of Cosmetic Science |
| June 12, 2026 | Source | New source added: Hexapeptide-11 is a novel modulator of the proteostasis network in human diploid fibroblastspubmed.ncbi.nlm.nih.gov/25974626/ | — |
| Redox Biology (Elsevier) |
| June 12, 2026 | Source | New source added: Pregnyl (chorionic gonadotropin for injection, USP) Prescribing Information — NDA 017692accessdata.fda.gov/drugsatfda_docs/label/2011/017692s021lbl.pdf | — |
| U.S. Food and Drug Administration |
| June 12, 2026 | Source | New source added: Preserving fertility in the hypogonadal patient: an updatepmc.ncbi.nlm.nih.gov/articles/PMC4378070/ | — |
| Asian Journal of Andrology / PMC |
| June 12, 2026 | Source | New source added: The effect of human chorionic gonadotropin (hCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis (DARE review)ncbi.nlm.nih.gov/books/NBK66355/ | — |
| NCBI Bookshelf / Database of Abstracts of Reviews of Effects |
| June 12, 2026 | Source | New source added: The Safety of Human Chorionic Gonadotropin Monotherapy Among Men With Previous Exogenous Testosterone Usepmc.ncbi.nlm.nih.gov/articles/PMC9271319/ | — |
| Cureus |
| June 12, 2026 | Source | New source added: Management Outcomes in Males With Hypogonadotropic Hypogonadism Treated With Gonadotropinspmc.ncbi.nlm.nih.gov/articles/PMC10063211/ | — |
| Cureus |
| June 12, 2026 | Source | New source added: Testosterone versus hCG in Hypogonadotropic Hypogonadism: Comparing Clinical Effects and Evaluating Current Practicepubmed.ncbi.nlm.nih.gov/35187206/ | — |
| Global Pediatric Health |
| June 12, 2026 | Source | New source added: Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiencypubmed.ncbi.nlm.nih.gov/20484472/ | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse Leydig cells in vitropmc.ncbi.nlm.nih.gov/articles/PMC5217336/ | — |
| Reproductive Biology and Endocrinology / BioMed Central |
| June 12, 2026 | Source | New source added: Imunovir 500mg Tablets — Summary of Product Characteristics (SmPC)medicines.org.uk/emc/product/2824/smpc | — |
| Electronic Medicines Compendium (UK) |
| June 12, 2026 | Source | New source added: A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patientspubmed.ncbi.nlm.nih.gov/34103950/ | — |
| Dove Medical Press |
| June 12, 2026 | Source | New source added: Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Coursepmc.ncbi.nlm.nih.gov/articles/PMC8619495/ | — |
| Viruses (MDPI) |
| June 12, 2026 | Source | New source added: Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled studypubmed.ncbi.nlm.nih.gov/8876359/ | — |
| International Journal of STD and AIDS |
| June 12, 2026 | Source | New source added: The Efficacy of Inosine Pranobex in Preventing the Acquired Immunodeficiency Syndrome in Patients with Human Immunodeficiency Virus Infection (Scandinavian Isoprinosine Study Group)pubmed.ncbi.nlm.nih.gov/1693173/ | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: Efficacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trialpubmed.ncbi.nlm.nih.gov/36246300/ | — |
| Advanced Therapeutics (Wiley) |
| June 12, 2026 | Source | New source added: Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: Phase 4, randomised, placebo-controlled, double-blind studypmc.ncbi.nlm.nih.gov/articles/PMC5100179/ | — |
| BMC Infectious Diseases |
| June 12, 2026 | Source | New source added: SCENESSE (afamelanotide) Prescribing Informationaccessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf | — |
| U.S. Food and Drug Administration |
| June 12, 2026 | Source | New source added: Melanotan IIen.wikipedia.org/wiki/Melanotan_II | — |
| June 12, 2026 | Source | New source added: Melanotan IIdermnetnz.org/topics/melanotan-ii | — |
| DermNet New Zealand |
| June 12, 2026 | Source | New source added: Eruptive dysplastic nevi following melanotan usepubmed.ncbi.nlm.nih.gov/22425244/ | — |
| Actas Dermosifiliograficas |
| June 12, 2026 | Source | New source added: Melanotan-associated melanoma in situpubmed.ncbi.nlm.nih.gov/22724573/ | — |
| Australasian Journal of Dermatology |
| June 12, 2026 | Source | New source added: Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan IIpubmed.ncbi.nlm.nih.gov/11035391/ | — |
| International Journal of Impotence Research |
| June 12, 2026 | Source | New source added: Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunctionpubmed.ncbi.nlm.nih.gov/11018622/ | — |
| Urology |
| June 12, 2026 | Source | New source added: Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical studysciencedirect.com/science/article/pii/0024320596001609 | — |
| Life Sciences (Elsevier) |
| June 12, 2026 | Source | New source added: Matrixyl 3000 — Official Product Pagecrodabeauty.com/en-gb/products/product/3007-matrixyl_1_3000 | — |
| Croda Beauty (Sederma) |
| June 12, 2026 | Source | New source added: Palmitoyl tetrapeptide-7en.wikipedia.org/wiki/Palmitoyl_tetrapeptide-7 | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmeticsjournals.sagepub.com/doi/10.1177/1091581818807863 | — |
| International Journal of Toxicology (Cosmetic Ingredient Review) |
| June 12, 2026 | Source | New source added: Topical Peptide Treatments with Effective Anti-Aging Resultsmdpi.com/2079-9284/4/2/16 | — |
| MDPI Cosmetics |
| June 12, 2026 | Source | New source added: Clinical evidence of the efficacy and safety of a new multi-peptide anti-aging topical eye serumpubmed.ncbi.nlm.nih.gov/37335808/ | — |
| Journal of Cosmetic Dermatology |
| June 12, 2026 | Source | New source added: Palmitoyl pentapeptide-4 - Wikipediaen.wikipedia.org/wiki/Palmitoyl_pentapeptide-4 | — |
| June 12, 2026 | Source | New source added: Safety Assessment of Myristoyl Pentapeptide-4, Palmitoyl Pentapeptide-4, and Pentapeptide-4 as Used in Cosmeticscir-safety.org/supplementaldoc/safety-assessment-myristoyl-pent… | — |
| Cosmetic Ingredient Review |
| June 12, 2026 | Source | New source added: The pentapeptide KTTKS promoting the expressions of type I collagen and transforming growth factor-beta of tendon cellsonlinelibrary.wiley.com/doi/abs/10.1002/jor.20455 | — |
| Journal of Orthopaedic Research |
| June 12, 2026 | Source | New source added: The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activitypmc.ncbi.nlm.nih.gov/articles/PMC6832239/ | — |
| Molecules |
| June 12, 2026 | Source | New source added: Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS)pmc.ncbi.nlm.nih.gov/articles/PMC4131521/ | — |
| Biomolecules and Therapeutics |
| June 12, 2026 | Source | New source added: Topically applied KTTKS: a reviewpubmed.ncbi.nlm.nih.gov/21535443/ | — |
| International Journal of Cosmetic Science |
| June 12, 2026 | Source | New source added: Topical palmitoyl pentapeptide provides improvement in photoaged human facial skinpubmed.ncbi.nlm.nih.gov/18492182/ | — |
| International Journal of Cosmetic Science |
| June 12, 2026 | Source | New source added: A pentapeptide from type I procollagen promotes extracellular matrix productionpubmed.ncbi.nlm.nih.gov/8486721/ | — |
| Journal of Biological Chemistry |
| June 12, 2026 | Source | New source added: LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activitypubmed.ncbi.nlm.nih.gov/27117377/ | — |
| Pharmacological Reports |
| June 12, 2026 | Source | New source added: LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cellspubmed.ncbi.nlm.nih.gov/11015447/ | — |
| Journal of Experimental Medicine |
| June 12, 2026 | Source | New source added: Oral intake of phenylbutyrate with or without vitamin D3 upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosispmc.ncbi.nlm.nih.gov/articles/PMC3637063/ | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infectionspmc.ncbi.nlm.nih.gov/articles/PMC7565865/ | — |
| Frontiers in Immunology |
| June 12, 2026 | Source | New source added: The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Woundsfrontiersin.org/journals/immunology/articles/10.3389/fimmu.2013.… | — |
| Frontiers in Immunology |
| June 12, 2026 | Source | New source added: In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37pubmed.ncbi.nlm.nih.gov/17805349/ | — |
| Journal of Investigative Dermatology |
| June 12, 2026 | Source | New source added: Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trialpubmed.ncbi.nlm.nih.gov/24888447/ | — |
| Wound Repair and Regeneration / Wiley |
| June 12, 2026 | Source | New source added: Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trialpmc.ncbi.nlm.nih.gov/articles/PMC9298190/ | — |
| Wound Repair and Regeneration / Wiley |
| June 12, 2026 | Source | New source added: SCALE Trial Summary - Wiki Journal Clubwikijournalclub.org/wiki/SCALE | — |
| June 12, 2026 | Source | New source added: High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination (case series)pmc.ncbi.nlm.nih.gov/articles/PMC8788265/ | — |
| MDPI / Endocrines |
| June 12, 2026 | Source | New source added: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure (LEADER sub-analysis)jacc.org/doi/10.1016/j.jacc.2019.12.063 | — |
| Journal of the American College of Cardiology |
| June 12, 2026 | Source | New source added: SAXENDA (liraglutide) injection - FDA Prescribing Informationaccessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf | — |
| U.S. Food and Drug Administration / Novo Nordisk |
| June 12, 2026 | Source | New source added: Liraglutide and Renal Outcomes in Type 2 Diabetes (LEADER renal sub-analysis)pubmed.ncbi.nlm.nih.gov/28854085/ | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial)pubmed.ncbi.nlm.nih.gov/27295427/ | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE trial)nejm.org/doi/full/10.1056/NEJMoa1411892 | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: Liraglutide - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov/books/NBK608007/ | — |
| NCBI Bookshelf / StatPearls |
| June 12, 2026 | Source | New source added: Oxytocin functions: an overviewmedcraveonline.com/MOJAP/oxytocin-functions-an-overview.html | — |
| MedCrave Online |
| June 12, 2026 | Source | New source added: Oxytocin: its mechanism of action and receptor signalling in the myometriumpubmed.ncbi.nlm.nih.gov/24888645/ | — |
| PubMed / National Library of Medicine |
| June 12, 2026 | Source | New source added: Oxytocin and Women Postpartum Depression: A Systematic Review of Randomized Controlled Trialspmc.ncbi.nlm.nih.gov/articles/PMC10122502/ | — |
| PMC / National Library of Medicine |
| June 12, 2026 | Source | New source added: Oxytocin and postpartum depression: A systematic reviewpubmed.ncbi.nlm.nih.gov/32683141/ | — |
| PubMed / National Library of Medicine |
| June 12, 2026 | Source | New source added: Effects of multiple-dose intranasal oxytocin administration on social responsiveness in children with autism: a randomized, placebo-controlled trialpmc.ncbi.nlm.nih.gov/articles/PMC10117268/ | — |
| PMC / National Library of Medicine |
| June 12, 2026 | Source | New source added: The neurobiological impact of oxytocin in mental health disorders: a comprehensive reviewpmc.ncbi.nlm.nih.gov/articles/PMC11981257/ | — |
| PMC / National Library of Medicine |
| June 12, 2026 | Source | New source added: Oxytocin - StatPearlsncbi.nlm.nih.gov/books/NBK507848/ | — |
| StatPearls Publishing / NCBI Bookshelf |
| June 12, 2026 | Source | New source added: A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naive Participants With Active Psoriatic Arthritis — ClinicalTrials.gov NCT06878404clinicaltrials.gov/study/NCT06878404 | — |
| ClinicalTrials.gov / NIH |
| June 12, 2026 | Source | New source added: Once-daily oral icotrokinra versus placebo and deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2) — ScienceDirect abstractsciencedirect.com/science/article/abs/pii/S0140673625015764 | — |
| The Lancet |
| June 12, 2026 | Source | New source added: ICONIC-LEAD Phase 3: Icotrokinra for Moderate-to-Severe Plaque Psoriasis — Results Through Week 24 (ScienceDirect abstract)sciencedirect.com/science/article/abs/pii/S0003496725024781 | — |
| June 12, 2026 | Source | New source added: FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide — Johnson & Johnson press releaseprnewswire.com/news-releases/fda-approval-of-icotyde-icotrokinr… | — |
| Johnson & Johnson / PR Newswire |
| June 12, 2026 | Source | New source added: Safety and efficacy of oral icotrokinra for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trialsfrontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.… | — |
| Frontiers in Immunology |
| June 12, 2026 | Source | New source added: Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasispmc.ncbi.nlm.nih.gov/articles/PMC12890502/ | — |
| PubMed Central / NCBI |
| June 12, 2026 | Source | New source added: Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signalingpmc.ncbi.nlm.nih.gov/articles/PMC12354395/ | — |
| PubMed Central / NCBI |
| June 12, 2026 | Source | New source added: Label: ICOTYDE (icotrokinra) tablet, film coated — DailyMed, NIHdailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aee3c963-edc0-4252-8… | — |
| U.S. National Library of Medicine / Janssen Biotech Inc. |
| June 12, 2026 | Source | New source added: AOD9604 - Wikipediaen.wikipedia.org/wiki/AOD9604 | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: Detection and in vitro metabolism of AOD9604pubmed.ncbi.nlm.nih.gov/25208511/ | — |
| Drug Testing and Analysis |
| June 12, 2026 | Source | New source added: Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Healthjofem.org/index.php/jofem/article/view/213/278 | — |
| Journal of Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Safety and Tolerability of the Hexadecapeptide AOD9604 in Humansjofem.org/index.php/jofem/article/view/157/194 | — |
| Journal of Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out miceacademic.oup.com/endo/article/142/12/5182/2988749 | — |
| Endocrinology (Oxford Academic) |
| June 12, 2026 | Source | New source added: Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragmentpubmed.ncbi.nlm.nih.gov/11673763/ | — |
| International Journal of Obesity |
| June 12, 2026 | Source | New source added: Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty ratspubmed.ncbi.nlm.nih.gov/11116208/ | — |
| Journal of Molecular Endocrinology |
| June 12, 2026 | Source | New source added: Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormonepubmed.ncbi.nlm.nih.gov/11146367/ | — |
| Hormone Research |
| June 12, 2026 | Source | New source added: Pralmorelin — History and Discovery (Peptide Initiative)peptideinitiative.com/peptide-chronicles/pralmorelin | — |
| Peptide Initiative |
| June 12, 2026 | Source | New source added: GHRP-4 — Growth Hormone Releasing Peptide (ProSpec product monograph)prospecbio.com/ghrp4 | — |
| ProSpec Bio |
| June 12, 2026 | Source | New source added: Growth hormone-releasing peptides: clinical and basic aspectspubmed.ncbi.nlm.nih.gov/8950613/ | — |
| June 12, 2026 | Source | New source added: Growth hormone-releasing peptides and their analogs — Camanni F, Ghigo E, Arvat Epubmed.ncbi.nlm.nih.gov/9465289/ | — |
| Frontiers in Neuroendocrinology |
| June 12, 2026 | Source | New source added: Growth hormone-releasing peptide (GHRP) — Bowers CYpubmed.ncbi.nlm.nih.gov/9893708/ | — |
| Cell Mol Life Sci |
| June 12, 2026 | Source | New source added: The Safety and Efficacy of Growth Hormone Secretagoguespmc.ncbi.nlm.nih.gov/articles/PMC5632578/ | — |
| Sexual Medicine Reviews |
| June 12, 2026 | Source | New source added: Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effectspmc.ncbi.nlm.nih.gov/articles/PMC5392015/ | — |
| SAGE Open Medicine |
| June 12, 2026 | Source | New source added: Growth Hormone-Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactionspmc.ncbi.nlm.nih.gov/articles/PMC12869127/ | — |
| PMC / NCBI |
| June 12, 2026 | Source | New source added: Ghrelin accelerates wound healing through GHS-R1a-mediated MAPK-NF-kappaB/GR signaling pathways in combined radiation and burn injury in ratspubmed.ncbi.nlm.nih.gov/27271793/ | — |
| Scientific Reports |
| June 12, 2026 | Source | New source added: The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numberspmc.ncbi.nlm.nih.gov/articles/PMC7890143/ | — |
| Journal of Cachexia, Sarcopenia and Muscle |
| June 12, 2026 | Source | New source added: ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexiapmc.ncbi.nlm.nih.gov/articles/PMC5834076/ | — |
| Annals of Oncology |
| June 12, 2026 | Source | New source added: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trialspubmed.ncbi.nlm.nih.gov/26906526/ | — |
| Lancet Oncology |
| June 12, 2026 | Source | New source added: Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trialacpjournals.org/doi/10.7326/0003-4819-149-9-200811040-00003 | — |
| Annals of Internal Medicine |
| June 12, 2026 | Source | New source added: Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjectspubmed.ncbi.nlm.nih.gov/8954023/ | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Ipamorelin, the first selective growth hormone secretagoguepubmed.ncbi.nlm.nih.gov/9849822/ | — |
| European Journal of Endocrinology |
| June 12, 2026 | Source | New source added: The Growth Hormone Secretagogue Receptor: Its Intracellular Signaling and Regulationpmc.ncbi.nlm.nih.gov/articles/PMC3975427/ | — |
| Frontiers in Endocrinology |
| June 12, 2026 | Source | New source added: Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial (EurekAlert press release, McGill University / Wayne Carey MD)eurekalert.org/news-releases/990464 | — |
| June 12, 2026 | Source | New source added: Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Reviewpmc.ncbi.nlm.nih.gov/articles/PMC12595317/ | — |
| Medical Sciences |
| June 12, 2026 | Source | New source added: The potential of GHK as an anti-aging peptidepmc.ncbi.nlm.nih.gov/articles/PMC8789089/ | — |
| Aging Pathobiology and Therapeutics |
| June 12, 2026 | Source | New source added: Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathwaypmc.ncbi.nlm.nih.gov/articles/PMC9354777/ | — |
| Frontiers in Molecular Biosciences |
| June 12, 2026 | Source | New source added: A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHKpubmed.ncbi.nlm.nih.gov/22937864/ | — |
| Genome Medicine |
| June 12, 2026 | Source | New source added: GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regenerationpmc.ncbi.nlm.nih.gov/articles/PMC4508379/ | — |
| BioMed Research International |
| June 12, 2026 | Source | New source added: Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Datapmc.ncbi.nlm.nih.gov/articles/PMC6073405/ | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: Copper peptide GHK-Cu - Wikipediaen.wikipedia.org/wiki/Copper_peptide_GHK-Cu | — |
| June 12, 2026 | Source | New source added: Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Reviewmedsci.org/v22p4175.htm | — |
| International Journal of Medical Sciences (Ivyspring) |
| June 12, 2026 | Source | New source added: Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growthpubmed.ncbi.nlm.nih.gov/27489425/ | — |
| Annals of Dermatology |
| June 12, 2026 | Source | New source added: The potential of GHK as an anti-aging peptidepmc.ncbi.nlm.nih.gov/articles/PMC8789089/ | — |
| Biomolecules |
| June 12, 2026 | Source | New source added: The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Healthpmc.ncbi.nlm.nih.gov/articles/PMC3359723/ | — |
| Oxidative Medicine and Cellular Longevity |
| June 12, 2026 | Source | New source added: GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regenerationpmc.ncbi.nlm.nih.gov/articles/PMC4508379/ | — |
| BioMed Research International |
| June 12, 2026 | Source | New source added: Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Datapmc.ncbi.nlm.nih.gov/articles/PMC6073405/ | — |
| International Journal of Molecular Sciences (MDPI) |
| June 12, 2026 | Source | New source added: Efficacy of collagen peptide supplementation on bone and muscle health: a meta-analysisfrontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.16… | — |
| Frontiers in Nutrition |
| June 12, 2026 | Source | New source added: Collagen supplementation in skin and orthopedic diseases: A review of the literaturepmc.ncbi.nlm.nih.gov/articles/PMC10102402/ | — |
| Heliyon |
| June 12, 2026 | Source | New source added: Evaluation of the Efficacy and Safety of CollaSel PRO Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis: A Double-Blind, Placebo-Controlled, Randomized Clinical Trialpmc.ncbi.nlm.nih.gov/articles/PMC12156922/ | — |
| Journal of Clinical Medicine |
| June 12, 2026 | Source | New source added: Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopeniapubmed.ncbi.nlm.nih.gov/32131366/ | — |
| Journal of Musculoskeletal and Neuronal Interactions |
| June 12, 2026 | Source | New source added: Oral administration of hydrolyzed collagen alleviates pain and enhances functionality in knee osteoarthritis: Results from a randomized, double-blind, placebo-controlled studypmc.ncbi.nlm.nih.gov/articles/PMC11745964/ | — |
| Contemporary Clinical Trials Communications |
| June 12, 2026 | Source | New source added: The Effects of Type I Collagen Hydrolysate Supplementation on Bones, Muscles, and Joints: A Systematic Revieworthopedicreviews.openmedicalpublishing.org/article/129086-the-effects-of-type-i-collagen-hy… | — |
| Orthopedic Reviews |
| June 12, 2026 | Source | New source added: Analgesic efficacy of collagen peptide in knee osteoarthritis: a meta-analysis of randomized controlled trialspmc.ncbi.nlm.nih.gov/articles/PMC10505327/ | — |
| Journal of Orthopaedic Surgery and Research |
| June 12, 2026 | Source | New source added: Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women — A Randomized Controlled Studypmc.ncbi.nlm.nih.gov/articles/PMC5793325/ | — |
| Nutrients |
| June 12, 2026 | Source | New source added: Cerebrolysin: Cognitive Vitality Ratingalzdiscovery.org/cognitive-vitality/ratings/cerebrolysin | — |
| Alzheimer's Drug Discovery Foundation |
| June 12, 2026 | Source | New source added: Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysinpubmed.ncbi.nlm.nih.gov/20500802/ | — |
| European Journal of Neurology |
| June 12, 2026 | Source | New source added: Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agentpubmed.ncbi.nlm.nih.gov/12111446/ | — |
| Journal of Neural Transmission |
| June 12, 2026 | Source | New source added: Combined citicoline and Cerebrolysin for neuroprotection in traumatic brain injury: a retrospective cohort analysispmc.ncbi.nlm.nih.gov/articles/PMC12705382/ | — |
| Frontiers in Neurology |
| June 12, 2026 | Source | New source added: Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysispmc.ncbi.nlm.nih.gov/articles/PMC10046100/ | — |
| Brain Sciences, MDPI |
| June 12, 2026 | Source | New source added: Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trialskarger.com/dem/article/39/5-6/332/98339/Cerebrolysin-in-Mil… | — |
| Dementia and Geriatric Cognitive Disorders, Karger |
| June 12, 2026 | Source | New source added: Cerebrolysin for acute ischaemic stroke (Cochrane Review, 7th edition)cochrane.org/evidence/CD007026_cerebrolysin-acute-ischaemic-s… | — |
| Cochrane |
| June 12, 2026 | Source | New source added: Calcitonin Salmon Injection — Full Prescribing Information (DailyMed)dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ece693d8-1832-… | — |
| U.S. National Library of Medicine / FDA |
| June 12, 2026 | Source | New source added: Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fracturespmc.ncbi.nlm.nih.gov/articles/PMC8567816/ | — |
| Orthopedic Reviews |
| June 12, 2026 | Source | New source added: The safety and efficacy of long-term use of calcitonin analogs in the treatment of osteoporosis in the elderly: a pharmacovigilance and RCT meta-analysispmc.ncbi.nlm.nih.gov/articles/PMC12515915/ | — |
| Frontiers in Pharmacology |
| June 12, 2026 | Source | New source added: Efficacy of calcitonin for treating acute pain associated with osteoporotic vertebral compression fracture: an updated systematic reviewpubmed.ncbi.nlm.nih.gov/32188529/ | — |
| Canadian Journal of Emergency Medicine |
| June 12, 2026 | Source | New source added: Calcitonin — StatPearlsncbi.nlm.nih.gov/books/NBK537269/ | — |
| StatPearls / NCBI Bookshelf (NIH) |
| June 12, 2026 | Source | New source added: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study (PROOF)pubmed.ncbi.nlm.nih.gov/10996576/ | — |
| American Journal of Medicine |
| June 12, 2026 | Source | New source added: Cagrilintide-semaglutide as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3)pubmed.ncbi.nlm.nih.gov/42251856/ | — |
| The Lancet |
| June 12, 2026 | Source | New source added: Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management (phase 1b trial)thelancet.com/journals/lancet/article/PIIS0140-6736(21)00845-X… | — |
| The Lancet |
| June 12, 2026 | Source | New source added: The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapiesthe-innovation.org/article/doi/10.59717/j.xinn-med.2025.100150 | — |
| The Innovation Medicine |
| June 12, 2026 | Source | New source added: REDEFINE 1 and REDEFINE 2: Greater Weight Loss With Combined Cagrilintide-Semaglutide vs. Either Drug Alone or Placeboacc.org/Latest-in-Cardiology/Journal-Scans/2025/07/02/14… | — |
| American College of Cardiology |
| June 12, 2026 | Source | New source added: Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight managementprnewswire.com/news-releases/novo-nordisk-files-for-fda-approva… | — |
| Novo Nordisk / PR Newswire |
| June 12, 2026 | Source | New source added: Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptorspmc.ncbi.nlm.nih.gov/articles/PMC11982234/ | — |
| Nature Communications |
| June 12, 2026 | Source | New source added: Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes (phase 2 trial)pubmed.ncbi.nlm.nih.gov/37364590/ | — |
| The Lancet |
| June 12, 2026 | Source | New source added: Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)pubmed.ncbi.nlm.nih.gov/40544433/ | — |
| New England Journal of Medicine |
| June 12, 2026 | Source | New source added: NeuroFGL: Development of a novel FGL therapy and translational tests for regenerative treatment of neurological disorders (EU CORDIS FP7 project 278006)cordis.europa.eu/project/id/278006/reporting | — |
| June 12, 2026 | Source | New source added: The neural cell adhesion molecule-derived peptide, FGL, attenuates lipopolysaccharide-induced changes in glia in a CD200-dependent mannerpubmed.ncbi.nlm.nih.gov/23337536/ | — |
| June 12, 2026 | Source | New source added: Impact of the Neural Cell Adhesion Molecule-Derived Peptide FGL on Seizure Progression and Cellular Alterations in the Mouse Kindling Model (PMC)pmc.ncbi.nlm.nih.gov/articles/PMC3963124/ | — |
| June 12, 2026 | Source | New source added: The synthetic NCAM mimetic peptide FGL mobilizes neural stem cells in vitro and in vivopubmed.ncbi.nlm.nih.gov/24817672/ | — |
| June 12, 2026 | Source | New source added: A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35pubmed.ncbi.nlm.nih.gov/17223274/ | — |
| June 12, 2026 | Source | New source added: Peptide Sparks Synaptic Plasticity, Improves Memory in Rodents (ALZFORUM, covering Esteban et al. PLoS Biology 2012)alzforum.org/news/research-news/peptide-sparks-synaptic-plast… | — |
| June 12, 2026 | Source | New source added: Tolerability, Safety and Pharmacokinetics of the FGLL Peptide, a Novel Mimetic of Neural Cell Adhesion Molecule, Following Intranasal Administration in Healthy Volunteers (Clinical Pharmacokinetics, 2007)link.springer.com/article/10.2165/00003088-200746040-00007 | — |
| Clinical Pharmacokinetics / Springer |
| June 12, 2026 | Source | New source added: A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult both in vitro and in vivopubmed.ncbi.nlm.nih.gov/16197499/ | — |
| June 12, 2026 | Source | New source added: Epitalon: Evidence, telomere protection, aging, and longevity reviewgethealthspan.com/research/article/epitalon | — |
| June 12, 2026 | Source | New source added: Peptide Epitalon activates chromatin at the old agepubmed.ncbi.nlm.nih.gov/14647006/ | — |
| Neuro Endocrinology Letters |
| June 12, 2026 | Source | New source added: Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeyspubmed.ncbi.nlm.nih.gov/11524632/ | — |
| Neuro Endocrinology Letters |
| June 12, 2026 | Source | New source added: Structural basis for the inhibition of activin signalling by follistatinpmc.ncbi.nlm.nih.gov/articles/PMC1409725/ | — |
| The EMBO Journal |
| June 12, 2026 | Source | New source added: A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophypubmed.ncbi.nlm.nih.gov/25322757/ | — |
| Molecular Therapy |
| June 12, 2026 | Source | New source added: Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Propertiespmc.ncbi.nlm.nih.gov/articles/PMC11943447/ | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cellspubmed.ncbi.nlm.nih.gov/12937682/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Epitalon: What can this peptide do for telomere protection, aging, and longevity, and where is the evidence?gethealthspan.com/research/article/epitalon | — |
| Healthspan |
| June 12, 2026 | Source | New source added: Epitalon influences pineal secretion in stress-exposed rats in the daytimepubmed.ncbi.nlm.nih.gov/12500171/ | — |
| Neuro Endocrinology Letters |
| June 12, 2026 | Source | New source added: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activitypmc.ncbi.nlm.nih.gov/articles/PMC12411320/ | — |
| Biogerontology (Springer) |
| June 12, 2026 | Source | New source added: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cellspubmed.ncbi.nlm.nih.gov/12937682/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly peoplepubmed.ncbi.nlm.nih.gov/17969590/ | — |
| Advances in Gerontology |
| June 12, 2026 | Source | New source added: Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly peoplepubmed.ncbi.nlm.nih.gov/15452611/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeyspubmed.ncbi.nlm.nih.gov/11524632/ | — |
| Neuro Endocrinology Letters |
| June 12, 2026 | Source | New source added: Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Propertiespmc.ncbi.nlm.nih.gov/articles/PMC11943447/ | — |
| International Journal of Molecular Sciences (MDPI) |
| June 12, 2026 | Source | New source added: Epitalon — Wikipediaen.wikipedia.org/wiki/Epitalon | — |
| Wikipedia |
| June 12, 2026 | Source | New source added: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activitylink.springer.com/article/10.1007/s10522-025-10315-x | — |
| Biogerontology (Springer Nature) |
| June 12, 2026 | Source | New source added: Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosapubmed.ncbi.nlm.nih.gov/12195242/ | — |
| Neuroendocrinology Letters |
| June 12, 2026 | Source | New source added: Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-uppubmed.ncbi.nlm.nih.gov/22451889/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated agingpubmed.ncbi.nlm.nih.gov/17426848/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cellspubmed.ncbi.nlm.nih.gov/12937682/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Propertiespmc.ncbi.nlm.nih.gov/articles/PMC11943447/ | — |
| International Journal of Molecular Sciences (MDPI) |
| June 12, 2026 | Source | New source added: Mechanism of delta-sleep inducing peptide geroprotective activitypubmed.ncbi.nlm.nih.gov/21809625/ | — |
| June 12, 2026 | Source | New source added: Synthetic delta-sleep-inducing peptide improves sleep in insomniacspubmed.ncbi.nlm.nih.gov/6112579/ | — |
| Lancet |
| June 12, 2026 | Source | New source added: Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brainpubmed.ncbi.nlm.nih.gov/2547200/ | — |
| June 12, 2026 | Source | New source added: Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptorspubmed.ncbi.nlm.nih.gov/6328354/ | — |
| Neuropsychobiology |
| June 12, 2026 | Source | New source added: Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP)pubmed.ncbi.nlm.nih.gov/6548966/ | — |
| European Neurology |
| June 12, 2026 | Source | New source added: Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot studypubmed.ncbi.nlm.nih.gov/6548970/ | — |
| European Neurology |
| June 12, 2026 | Source | New source added: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind studypubmed.ncbi.nlm.nih.gov/1299794/ | — |
| June 12, 2026 | Source | New source added: Delta sleep-inducing peptide (DSIP): a still unresolved riddlepubmed.ncbi.nlm.nih.gov/16539679/ | — |
| Journal of Neurochemistry |
| June 12, 2026 | Source | New source added: Dihexa: Research Evidence and Safety Profilepeptideinsight.com/en/peptides/dihexa | — |
| June 12, 2026 | Source | New source added: Fosgonimeton — Alzforum Therapeutics Databasealzforum.org/therapeutics/fosgonimeton | — |
| June 12, 2026 | Source | New source added: Four papers by Athira CEO earn expressions of concernretractionwatch.com/2021/09/24/four-papers-by-athira-ceo-earn-expres… | — |
| June 12, 2026 | Source | New source added: AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathwaypmc.ncbi.nlm.nih.gov/articles/PMC8615599/ | — |
| Brain Sciences |
| June 12, 2026 | Source | New source added: Retraction: The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met Systempmc.ncbi.nlm.nih.gov/articles/PMC13095468/ | — |
| Journal of Pharmacology and Experimental Therapeutics |
| June 12, 2026 | Source | New source added: The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System (RETRACTED April 2025)pmc.ncbi.nlm.nih.gov/articles/PMC4201273/ | — |
| Journal of Pharmacology and Experimental Therapeutics |
| June 12, 2026 | Source | New source added: Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents (Notice of Concern, 2021)pmc.ncbi.nlm.nih.gov/articles/PMC3533412/ | — |
| Journal of Pharmacology and Experimental Therapeutics |
| June 12, 2026 | Source | New source added: INTRAROSA (prasterone) Prescribing Informationus.intrarosa.com/what-is-intrarosa | — |
| Endoceutics Inc. |
| June 12, 2026 | Source | New source added: Should Dehydroepiandrosterone Be Administered to Women?pmc.ncbi.nlm.nih.gov/articles/PMC9113789/ | — |
| PubMed Central |
| June 12, 2026 | Source | New source added: Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing IVF: a randomized controlled trialpmc.ncbi.nlm.nih.gov/articles/PMC4210503/ | — |
| PubMed Central |
| June 12, 2026 | Source | New source added: The Utilization of Dehydroepiandrosterone as a Sexual Hormone Precursor in Premenopausal and Postmenopausal Women: An Overviewpmc.ncbi.nlm.nih.gov/articles/PMC8781653/ | — |
| PubMed Central |
| June 12, 2026 | Source | New source added: The effect of dehydroepiandrosterone (DHEA) supplementation on estradiol levels in women: A dose-response and meta-analysis of randomized clinical trialspubmed.ncbi.nlm.nih.gov/34246664/ | — |
| PubMed |
| June 12, 2026 | Source | New source added: Effects of Dehydroepiandrosterone Supplementation on Cognitive Function and Quality of Life: The DHEA and Well-Ness (DAWN) Trialpmc.ncbi.nlm.nih.gov/articles/PMC2574781/ | — |
| PubMed Central |
| June 12, 2026 | Source | New source added: The Sex Hormone Precursors Dehydroepiandrosterone (DHEA) and Its Sulfate Ester Form (DHEAS): Molecular Mechanisms and Actions on Human Bodypmc.ncbi.nlm.nih.gov/articles/PMC12429729/ | — |
| PubMed Central |
| June 12, 2026 | Source | New source added: Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delaypmc.ncbi.nlm.nih.gov/articles/PMC12024793/ | — |
| Biomedicines (MDPI) |
| June 12, 2026 | Source | New source added: An open clinical trial of cortexin in treatment of brain ischemiapubmed.ncbi.nlm.nih.gov/25403301/ | — |
| June 12, 2026 | Source | New source added: The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysispmc.ncbi.nlm.nih.gov/articles/PMC9616232/ | — |
| ScienceDirect / PMC |
| June 12, 2026 | Source | New source added: Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in childrenmedcraveonline.com/JNSK/results-of-a-multicenter-study-on-the-effic… | — |
| MedCrave Journal of Neurology and Stroke |
| June 12, 2026 | Source | New source added: Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic strokepubmed.ncbi.nlm.nih.gov/24874316/ | — |
| June 12, 2026 | Source | New source added: Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study)pubmed.ncbi.nlm.nih.gov/30335070/ | — |
| June 12, 2026 | Source | New source added: Molecular Mechanisms of the Actions of Brain Peptide-Containing Drugs: Cortexinpubmed.ncbi.nlm.nih.gov/30499504/ | — |
| Neuroscience and Behavioral Physiology (Springer) |
| June 12, 2026 | Source | New source added: Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in ratspmc.ncbi.nlm.nih.gov/articles/PMC8279368/ | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Cortagen — Wikipediaen.wikipedia.org/wiki/Cortagen | — |
| June 12, 2026 | Source | New source added: Epigenetic Regulation of Aged Heterochromatin by Peptide Bioregulator Cortagenlink.springer.com/article/10.1007/s10989-014-9443-7 | — |
| International Journal of Peptide Research and Therapeutics |
| June 12, 2026 | Source | New source added: Neuroprotective Effects of Peptides during Ischemic Preconditioning (Zarubina and Shabanov 2016)pubmed.ncbi.nlm.nih.gov/26902350/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Modulatory Effects of Cortexin and Cortagen on Locomotor Activity and Anxiety-Related Behavior in Mice (Adriani et al.)benthamopenarchives.com/abstract.php?ArticleCode=TONEUROPPJ-2-22 | — |
| The Open Neuropsychopharmacology Journal |
| June 12, 2026 | Source | New source added: Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemiapubmed.ncbi.nlm.nih.gov/21476278/ | — |
| Eksperimental'naia i Klinicheskaia Farmakologiia |
| June 12, 2026 | Source | New source added: Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarraysemanticscholar.org/paper/Elucidation-of-the-effect-of-brain-cortex-… | — |
| Neuroendocrinology Letters |
| June 12, 2026 | Source | New source added: Tissue-specific effects of peptides (Khavinson VK; organotypic culture with Cortagen, Epithalon, Livagen, Vilon)pubmed.ncbi.nlm.nih.gov/11713572/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Effect of tetrapeptide cortagen on regeneration of sciatic nervepubmed.ncbi.nlm.nih.gov/11276314/ | — |
| Bulletin of Experimental Biology and Medicine |
| June 12, 2026 | Source | New source added: Topical GHK-Cu Gel for Acute Skin Wound Healing (NCT07437586)clinicaltrials.gov/study/NCT07437586 | — |
| ClinicalTrials.gov / NLM |
| June 12, 2026 | Source | New source added: Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trialeurekalert.org/news-releases/990464 | — |
| EurekAlert / AAAS |
| June 12, 2026 | Source | New source added: GHK-Cu: Beyond Cosmetic Hype — Clinical Uses, Stability and Compounding Tipsfagronacademy.us/blog/ghk-cu-beyond-cosmetic-hype | — |
| Fagron Academy |
| June 12, 2026 | Source | New source added: Effects of Topical Copper Tripeptide Complex on CO2 Laser-Resurfaced Skinpubmed.ncbi.nlm.nih.gov/16847171/ | — |
| Archives of Facial Plastic Surgery |
| June 12, 2026 | Source | New source added: GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regenerationpmc.ncbi.nlm.nih.gov/articles/PMC4508379/ | — |
| BioMed Research International |
| June 12, 2026 | Source | New source added: Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Datapubmed.ncbi.nlm.nih.gov/29986520/ | — |
| International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: Bulevirtide – Wikipediaen.wikipedia.org/wiki/Bulevirtide | — |
| June 12, 2026 | Source | New source added: Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (MYR301) – NCT03852719clinicaltrials.gov/study/NCT03852719 | — |
| June 12, 2026 | Source | New source added: FDA Grants Accelerated Approval to Gilead's Hepcludex (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virusgilead.com/news/news-details/2026/fda-grants-accelerated-ap… | — |
| Gilead Sciences |
| June 12, 2026 | Source | New source added: Comparative Efficacy of Bulevirtide, Interferons, and Nucleos(t)ide Analogs for Chronic Hepatitis Delta: A Systematic Review and Network Meta-Analysispmc.ncbi.nlm.nih.gov/articles/PMC13122728/ | — |
| June 12, 2026 | Source | New source added: Treating hepatitis D with bulevirtide – Real-world experience from 114 patientspmc.ncbi.nlm.nih.gov/articles/PMC10071092/ | — |
| June 12, 2026 | Source | New source added: Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48pmc.ncbi.nlm.nih.gov/articles/PMC11907224/ | — |
| June 12, 2026 | Source | New source added: Bulevirtide Monotherapy or in Combination for Chronic Hepatitis Delta: 2025 Updatepmc.ncbi.nlm.nih.gov/articles/PMC12644311/ | — |
| June 12, 2026 | Source | New source added: Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCPpmc.ncbi.nlm.nih.gov/articles/PMC10954734/ | — |
| Nature Communications |
| June 12, 2026 | Source | New source added: BPC-157: The peptide with big claims and scant evidencestatnews.com/2026/02/03/bpc-157-peptide-science-safety-regula… | — |
| STAT News |
| June 12, 2026 | Source | New source added: Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitropmc.ncbi.nlm.nih.gov/articles/PMC4425239/ | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functionspmc.ncbi.nlm.nih.gov/articles/PMC12195719/ | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Ratspmc.ncbi.nlm.nih.gov/articles/PMC8869603/ | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: Stable Gastric Pentadecapeptide BPC 157 and Wound Healingpmc.ncbi.nlm.nih.gov/articles/PMC8275860/ | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Managementpmc.ncbi.nlm.nih.gov/articles/PMC13026520/ | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healingpmc.ncbi.nlm.nih.gov/articles/PMC12446177/ | — |
| PubMed Central (PMC) |
| June 12, 2026 | Source | New source added: Potent induction of trained immunity by Saccharomyces cerevisiae beta-glucanspmc.ncbi.nlm.nih.gov/articles/PMC10896952/ | — |
| Frontiers in Immunology |
| June 12, 2026 | Source | New source added: Effects of a β-Glucan-Rich Blend of Medicinal Mushrooms and Botanicals on Innate Immune Cell Activation and Function Are Enhanced by a Very Low Dose of Bovine Colostrum Peptidespmc.ncbi.nlm.nih.gov/articles/PMC11207084/ | — |
| Nutrients (MDPI) |
| June 12, 2026 | Source | New source added: Role of beta-(1→3)(1→6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D culturespmc.ncbi.nlm.nih.gov/articles/PMC10938759/ | — |
| BMC Cancer |
| June 12, 2026 | Source | New source added: Effect and Tolerability of ABB C1 Beta-Glucan/Selenium/Zinc with Influenza or COVID-19 Vaccine: A Randomized, Double-Blind, Placebo-Controlled Studypmc.ncbi.nlm.nih.gov/articles/PMC8708701/ | — |
| Nutrients (MDPI) |
| June 12, 2026 | Source | New source added: The Effects of Orally Administered Beta-Glucan on Innate Immune Responses in Humans, a Randomized Open-Label Intervention Pilot-Studypmc.ncbi.nlm.nih.gov/articles/PMC4182605/ | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: β-Glucan Metabolic and Immunomodulatory Properties and Potential for Clinical Applicationpmc.ncbi.nlm.nih.gov/articles/PMC7770584/ | — |
| Journal of Fungi (MDPI) |
| June 12, 2026 | Source | New source added: Beta-Glucan Recognition by the Innate Immune System (PMC6618291)pmc.ncbi.nlm.nih.gov/articles/PMC6618291/ | — |
| Nature Reviews Immunology |
| June 12, 2026 | Source | New source added: Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trialspmc.ncbi.nlm.nih.gov/articles/PMC6479769/ | — |
| Molecules (MDPI) |
| June 12, 2026 | Source | New source added: The Peptide Argireline: The Importance of Local Application on the Skin, in the Light of Current Knowledgeeurekaselect.com/article/82902 | — |
| Letters in Drug Design and Discovery |
| June 12, 2026 | Source | New source added: Safety Assessment of Acetyl Hexapeptide-8 and Acetyl Hexapeptide-8 Amide as Used in Cosmeticscir-safety.org/sites/default/files/AcetylHexapeptide-8.pdf | — |
| Cosmetic Ingredient Review |
| June 12, 2026 | Source | New source added: Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modificationpmc.ncbi.nlm.nih.gov/articles/PMC5785486/ | — |
| Scientific Reports |
| June 12, 2026 | Source | New source added: Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia Complexion Analysis camera system for objective skin analysispmc.ncbi.nlm.nih.gov/articles/PMC10665711/ | — |
| GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW |
| June 12, 2026 | Source | New source added: Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm in Patients Receiving Botulinum Neurotoxin Therapypmc.ncbi.nlm.nih.gov/articles/PMC4747634/ | — |
| European Journal of Neurology |
| June 12, 2026 | Source | New source added: The anti-wrinkle efficacy of Argirelinepubmed.ncbi.nlm.nih.gov/23464592/ | — |
| Journal of Cosmetic and Laser Therapy |
| June 12, 2026 | Source | New source added: The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects: A Randomized, Placebo-Controlled Studypubmed.ncbi.nlm.nih.gov/23417317/ | — |
| American Journal of Clinical Dermatology |
| June 12, 2026 | Source | New source added: A synthetic hexapeptide (Argireline) with antiwrinkle activitypubmed.ncbi.nlm.nih.gov/18498523/ | — |
| International Journal of Cosmetic Science |
| June 12, 2026 | Source | New source added: Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis (NCT02039687)clinicaltrials.gov/study/NCT02039687 | — |
| ClinicalTrials.gov |
| June 12, 2026 | Source | New source added: Araim Pharmaceuticals Receives Orphan Drug Designation from the US FDA for ARA 290 for the Treatment of Sarcoidosisprnewswire.com/news-releases/araim-pharmaceuticals-receives-orp… | — |
| PR Newswire |
| June 12, 2026 | Source | New source added: Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Painiovs.arvojournals.org/article.aspx?articleid=2625918 | — |
| Investigative Ophthalmology and Visual Science |
| June 12, 2026 | Source | New source added: ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetespmc.ncbi.nlm.nih.gov/articles/PMC4365069/ | — |
| June 12, 2026 | Source | New source added: ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia responsepubmed.ncbi.nlm.nih.gov/24529189/ | — |
| Molecular Pain |
| June 12, 2026 | Source | New source added: ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber densitypubmed.ncbi.nlm.nih.gov/24136731/ | — |
| Molecular Medicine |
| June 12, 2026 | Source | New source added: Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Studypubmed.ncbi.nlm.nih.gov/23168581/ | — |
| Molecular Medicine |
| June 12, 2026 | Source | New source added: Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy (PMC3136748 — cites AOD9604 trial data)pmc.ncbi.nlm.nih.gov/articles/PMC3136748/ | — |
| Clinical Pharmacology and Therapeutics / PMC |
| June 12, 2026 | Source | New source added: Obesity Pharmacotherapy: Current Perspectives and Future Directions (PMC3584306 — includes AOD9604 Phase IIb failure summary)pmc.ncbi.nlm.nih.gov/articles/PMC3584306/ | — |
| Current Hypertension Reports / PMC |
| June 12, 2026 | Source | New source added: Obesity drug codenamed AOD9604 highly successful in trials (Phase IIa 12-week trial report)news-medical.net/news/2004/12/16/6878.aspx | — |
| News-Medical.net |
| June 12, 2026 | Source | New source added: Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Modelpubmed.ncbi.nlm.nih.gov/26275694/ | — |
| Annals of Clinical and Laboratory Science |
| June 12, 2026 | Source | New source added: Detection and in vitro metabolism of AOD9604pubmed.ncbi.nlm.nih.gov/25208511/ | — |
| Drug Testing and Analysis |
| June 12, 2026 | Source | New source added: Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormonepubmed.ncbi.nlm.nih.gov/11146367/ | — |
| Hormone Research |
| June 12, 2026 | Source | New source added: Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Miceacademic.oup.com/endo/article/142/12/5182/2988749 | — |
| Endocrinology (Oxford Academic) |
| June 12, 2026 | Source | New source added: Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragmentpubmed.ncbi.nlm.nih.gov/11673763/ | — |
| International Journal of Obesity and Related Metabolic Disorders |
| June 12, 2026 | Source | New source added: The role of AMPK in macrophage metabolism, function and polarisationpmc.ncbi.nlm.nih.gov/articles/PMC10709986/ | — |
| Journal of Translational Medicine |
| June 12, 2026 | Source | New source added: AMPK activates Parkin independent autophagy and improves post sepsis immune defense against secondary bacterial lung infectionspmc.ncbi.nlm.nih.gov/articles/PMC8196038/ | — |
| Scientific Reports |
| June 12, 2026 | Source | New source added: AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Reviewpmc.ncbi.nlm.nih.gov/articles/PMC8147799/ | — |
| Cells (MDPI) |
| June 12, 2026 | Source | New source added: AMPK-dependent and independent effects of AICAR and compound C on T-cell responsespmc.ncbi.nlm.nih.gov/articles/PMC5085118/ | — |
| Oncotarget |
| June 12, 2026 | Source | New source added: AMPK integrates metabolite and kinase-based immunometabolic control in macrophagespmc.ncbi.nlm.nih.gov/articles/PMC9842865/ | — |
| Molecular Metabolism |
| June 12, 2026 | Source | New source added: AMP-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotypepmc.ncbi.nlm.nih.gov/articles/PMC2756051/ | — |
| Journal of Immunology |
| June 12, 2026 | Source | New source added: AMPK-derived peptides reduce blood glucose levels but lead to fat retention in the liver of obese micepubmed.ncbi.nlm.nih.gov/24478381/ | — |
| Journal of Endocrinology |
| June 12, 2026 | Source | New source added: Current Synthesis and Systematic Review of Main Effects of Calf Blood Deproteinized Medicine (Actovegin) in Ischemic Strokepubmed.ncbi.nlm.nih.gov/32365943/ | — |
| MDPI / International Journal of Molecular Sciences |
| June 12, 2026 | Source | New source added: Actovegin in the management of patients after ischemic stroke: A systematic reviewjournals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.027049… | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Efficacy and safety of Actovegin in the treatment of intermittent claudication: results of an international, multicenter, placebo-controlled, randomized, phase IIIb clinical trial (APOLLO)pubmed.ncbi.nlm.nih.gov/36264097/ | — |
| Minerva Medica / International Angiology |
| June 12, 2026 | Source | New source added: ARTEMIDA Trial: A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairmentpmc.ncbi.nlm.nih.gov/articles/PMC5404405/ | — |
| American Heart Association / Stroke |
| June 12, 2026 | Source | New source added: Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patientspubmed.ncbi.nlm.nih.gov/19470838/ | — |
| American Diabetes Association / Diabetes Care |
| June 12, 2026 | Source | New source added: ACE-031 0.5 mg/kg q4wk and ACE-031 1.0 mg/kg q2wk in Duchenne Muscular Dystrophy (NCT01099761)ichgcp.net/clinical-trials-registry/NCT01099761 | — |
| June 12, 2026 | Source | New source added: UPDATE: ACE-031 Clinical Trials in Duchenne MDmda.org/quest/article/update-ace-031-clinical-trials-duc… | — |
| Muscular Dystrophy Association |
| June 12, 2026 | Source | New source added: Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Muscle Loss and Metabolic Dysfunctionpmc.ncbi.nlm.nih.gov/articles/PMC10272974/ | — |
| June 12, 2026 | Source | New source added: Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?pmc.ncbi.nlm.nih.gov/articles/PMC7571243/ | — |
| June 12, 2026 | Source | New source added: ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus)pmc.ncbi.nlm.nih.gov/articles/PMC12904423/ | — |
| PLOS ONE |
| June 12, 2026 | Source | New source added: Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trialpubmed.ncbi.nlm.nih.gov/27462804/ | — |
| Muscle & Nerve |
| June 12, 2026 | Source | New source added: A single ascending-dose study of muscle regulator ACE-031 in healthy volunteerspubmed.ncbi.nlm.nih.gov/23169607/ | — |
| Muscle & Nerve |
| June 12, 2026 | Source | New source added: The Why and How of Sequential and Combination Therapy in Osteoporosis: A Review of the Current Evidencepmc.ncbi.nlm.nih.gov/articles/PMC10118820/ | — |
| June 12, 2026 | Source | New source added: TYMLOS (abaloparatide) Injection — Full Prescribing Information, Initial U.S. Approval 2017nctr-crs.fda.gov/fdalabel/services/spl/set-ids/712143d9-e21e-4013… | — |
| June 12, 2026 | Source | New source added: Abaloparatide - StatPearls (NCBI Bookshelf)ncbi.nlm.nih.gov/books/NBK587447/ | — |
| StatPearls / NCBI |
| June 12, 2026 | Source | New source added: Effect of Abaloparatide on Vertebral, Nonvertebral, Major Osteoporotic, and Clinical Fractures in a Subset of Postmenopausal Women at Increased Risk of Fracture by FRAX Probabilitypmc.ncbi.nlm.nih.gov/articles/PMC6373333/ | — |
| June 12, 2026 | Source | New source added: The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial (ATOM)pmc.ncbi.nlm.nih.gov/articles/PMC10091818/ | — |
| Journal of Bone and Mineral Research |
| June 12, 2026 | Source | New source added: Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signalingpmc.ncbi.nlm.nih.gov/articles/PMC4701881/ | — |
| Endocrinology |
| June 12, 2026 | Source | New source added: ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosispmc.ncbi.nlm.nih.gov/articles/PMC6097601/ | — |
| Journal of Clinical Endocrinology and Metabolism |
| June 12, 2026 | Source | New source added: Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial (ACTIVE)pubmed.ncbi.nlm.nih.gov/27533157/ | — |
| JAMA |
| June 12, 2026 | Peptide | Peptide updated: NMN (Nicotinamide Mononucleotide) | NMN (Nicotinamide Mononucleotide) |
| NAD+ direct precursor nucleotide; key longevity compound. |
| June 12, 2026 | Peptide | Peptide updated: Thymosin Alpha-1 | Thymosin Alpha-1 |
| Immune system support |
| June 11, 2026 | Source | New source added: Spotlight on tesamorelin in HIV-associated lipodystrophypubmed.ncbi.nlm.nih.gov/22050344/ | — |
| BioDrugs |
| June 11, 2026 | Source | New source added: Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trialpmc.ncbi.nlm.nih.gov/articles/PMC6981288/ | — |
| Lancet HIV |
| June 11, 2026 | Source | New source added: Efficacy and Safety of Tesamorelin in People with HIV on Integrase Inhibitorspmc.ncbi.nlm.nih.gov/articles/PMC11365754/ | — |
| June 11, 2026 | Source | New source added: Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trialpmc.ncbi.nlm.nih.gov/articles/PMC9947601/ | — |
| June 11, 2026 | Source | New source added: Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trialpmc.ncbi.nlm.nih.gov/articles/PMC3764914/ | — |
| June 11, 2026 | Source | New source added: Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelfncbi.nlm.nih.gov/books/NBK539127/ | — |
| CADTH |
| June 11, 2026 | Source | New source added: Growth hormone and tesamorelin in the management of HIV-associated lipodystrophypmc.ncbi.nlm.nih.gov/articles/PMC3218714/ | — |
| June 11, 2026 | Source | New source added: Label: EGRIFTA SV - tesamorelin kit - DailyMeddailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-9… | — |
| U.S. National Library of Medicine / FDA |
| June 11, 2026 | Source | New source added: Ipamorelin - Wikipediaen.wikipedia.org/wiki/Ipamorelin | — |
| June 11, 2026 | Source | New source added: Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus (NCT00672074)clinicaltrials.gov/study/NCT00672074 | — |
| June 11, 2026 | Source | New source added: The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female ratspubmed.ncbi.nlm.nih.gov/10828840/ | — |
| Journal of Endocrinology |
| June 11, 2026 | Source | New source added: Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in ratspubmed.ncbi.nlm.nih.gov/10373343/ | — |
| Growth Hormone and IGF Research |
| June 11, 2026 | Source | New source added: Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientspubmed.ncbi.nlm.nih.gov/25331030/ | — |
| International Journal of Colorectal Disease |
| June 11, 2026 | Source | New source added: Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteerspubmed.ncbi.nlm.nih.gov/10496658/ | — |
| Pharmaceutical Research |
| June 11, 2026 | Source | New source added: Ipamorelin, the first selective growth hormone secretagoguepubmed.ncbi.nlm.nih.gov/9849822/ | — |
| European Journal of Endocrinology |
| June 11, 2026 | Source | New source added: Pharmacy Compounding Advisory Committee (PCAC) Meeting — Federal Register Notice, Bulk Drug Substances Including CJC-1295federalregister.gov/documents/2024/10/25/2024-24828/pharmacy-compoun… | — |
| U.S. Food and Drug Administration / Federal Register |
| June 11, 2026 | Source | New source added: CJC-1295 Use in Sports and Military Rules Explainedbscg.org/blogs/single/cjc-1295-use-in-sports-and-military… | — |
| Banned Substances Control Group (BSCG) |
| June 11, 2026 | Source | New source added: Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295 — Oxford Academic abstractacademic.oup.com/jcem/article-abstract/91/12/4792/2656274 | — |
| Oxford University Press / JCEM |
| June 11, 2026 | Source | New source added: Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295 — Oxford Academic abstractacademic.oup.com/jcem/article-abstract/91/3/799/2843281 | — |
| Oxford University Press / JCEM |
| June 11, 2026 | Source | New source added: Lipodystrophy study halted after patient deathaidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-p… | — |
| aidsmap |
| June 11, 2026 | Source | New source added: CJC-1295 — Wikipediaen.wikipedia.org/wiki/CJC-1295 | — |
| Wikimedia Foundation |
| June 11, 2026 | Source | New source added: Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analogpubmed.ncbi.nlm.nih.gov/17018654/ | — |
| Journal of Clinical Endocrinology & Metabolism |
| June 11, 2026 | Source | New source added: Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adultspubmed.ncbi.nlm.nih.gov/16352683/ | — |
| Journal of Clinical Endocrinology & Metabolism |
| June 11, 2026 | Source | New source added: Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspectivepmc.ncbi.nlm.nih.gov/articles/PMC10087310/ | — |
| Diabetes, Obesity and Metabolism |
| June 11, 2026 | Source | New source added: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)nejm.org/doi/abs/10.1056/NEJMoa2416394 | — |
| New England Journal of Medicine |
| June 11, 2026 | Source | New source added: Once-weekly tirzepatide versus once-daily insulin degludec in patients with type 2 diabetes (SURPASS-3)pubmed.ncbi.nlm.nih.gov/34370970/ | — |
| The Lancet |
| June 11, 2026 | Source | New source added: Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trialspmc.ncbi.nlm.nih.gov/articles/PMC11576767/ | — |
| International Journal of Clinical Pharmacy |
| June 11, 2026 | Source | New source added: Tirzepatide - StatPearlsncbi.nlm.nih.gov/books/NBK585056/ | — |
| NCBI Bookshelf / StatPearls |
| June 11, 2026 | Source | New source added: Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistpmc.ncbi.nlm.nih.gov/articles/PMC7526454/ | — |
| JCI Insight |
| June 11, 2026 | Source | New source added: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)nejm.org/doi/full/10.1056/NEJMoa2206038 | — |
| New England Journal of Medicine |
| June 11, 2026 | Source | New source added: Semaglutide - StatPearlsncbi.nlm.nih.gov/books/NBK603723/ | — |
| StatPearls Publishing / NCBI Bookshelf |
| June 11, 2026 | Source | New source added: Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesitypmc.ncbi.nlm.nih.gov/articles/PMC11090168/ | — |
| Frontiers in Endocrinology |
| June 11, 2026 | Source | New source added: A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellituspmc.ncbi.nlm.nih.gov/articles/PMC7434819/ | — |
| International Journal of Molecular Sciences |
| June 11, 2026 | Source | New source added: Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetespmc.ncbi.nlm.nih.gov/articles/PMC8736331/ | — |
| Cardiovascular Diabetology |
| June 11, 2026 | Source | New source added: Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trialspmc.ncbi.nlm.nih.gov/articles/PMC6099440/ | — |
| Diabetes, Obesity and Metabolism |
| June 11, 2026 | Source | New source added: Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial)nejm.org/doi/full/10.1056/NEJMoa2032183 | — |
| New England Journal of Medicine |
| June 11, 2026 | Source | New source added: WEGOVY (semaglutide) injection prescribing informationaccessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf | — |
| U.S. Food and Drug Administration |
| June 11, 2026 | Source | New source added: OZEMPIC (semaglutide) injection prescribing informationaccessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf | — |
| U.S. Food and Drug Administration |
| June 10, 2026 | Source | New source added: Regenerative and Protective Actions of the GHK-Cu Peptidemdpi.com/1422-0067/19/7/1987 | — |
| Int. J. Mol. Sci. (Pickart & Margolina, 2018) |
| June 10, 2026 | Source | New source added: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A — 503A Bulks List (Category 1 & 2)fda.gov/drugs/human-drug-compounding/503a-interim-bulks-… | — |
| U.S. Food and Drug Administration |
| June 10, 2026 | Source | New source added: Thymosin beta-4 activates ILK and promotes cardiac cell migration, survival and cardiac repairnature.com/articles/nature03000 | — |
| Nature (Bock-Marquette et al., 2004) |
| June 10, 2026 | Source | New source added: WADA Prohibited List — S2 Peptide Hormones, Growth Factors, Related Substances and Mimeticswada-ama.org/en/prohibited-list | — |
| World Anti-Doping Agency |
| June 10, 2026 | Source | New source added: Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Reviewncbi.nlm.nih.gov/pmc/articles/PMC11859134/ | — |
| Pharmaceuticals (Jozwiak et al., 2025) |
| June 5, 2026 | Research | New research: Retatrutide TRANSCEND-T2D-1 Phase 3: A1C Lowered up to ~2.0% and Weight up to 16.8% at 40 Weeks in Type 2 Diabetes (Eli Lilly, ADA 2026)investor.lilly.com/news-releases/news-release-details/lillys-triple… | Retatrutide |
| Phase 3 TRANSCEND-T2D-1 (manufacturer-reported topline; Eli Lilly press release dated May 28, 2026 ahead of the ADA 86th Scientific Sessions; full results scheduled for presentation at the ADA retatrutide symposium on June 6, 2026): in adults with type 2 diabetes, retatrutide — a |
| June 5, 2026 | Source | New source added: The Latest in GLP-1-Based Therapy to Be Featured at ADA 2026medscape.com/viewarticle/latest-glp-1-based-therapy-be-featur… | — |
| Medscape / American Diabetes Association |
| June 5, 2026 | Research | New research: ADA 2026 Scientific Sessions (June 5-8, New Orleans): First-Time CagriSema REIMAGINE Phase 3 and Oral GLP-1 Readouts Scheduledmedscape.com/viewarticle/latest-glp-1-based-therapy-be-featur… | CagriSema, Cagrilintide, Semaglutide, Elecoglipron |
| The American Diabetes Association's 86th Scientific Sessions run June 5-8, 2026 in New Orleans, with GLP-1-based therapies featured in seven of eight major clinical-trial result sessions. Phase 3 REIMAGINE 1, 2 and 3 data for CagriSema (cagrilintide + semaglutide, Novo Nordisk) a |
| June 4, 2026 | Research | New research: FDA Confirms 7-Peptide Agenda for July 23–24, 2026 PCAC 503A Bulks-List Review (BPC-157, KPV, TB-500, MOTS-C, DSIP/Emideltide, Semax, Epitalon)fda.gov/advisory-committees/advisory-committee-calendar/… | BPC-157, KPV, TB-500, MOTS-C, DSIP (Emideltide), Semax, Epitalon |
| FDA primary source (Pharmacy Compounding Advisory Committee meeting notice; page content current as of 2026-04-15). The PCAC will meet July 23–24, 2026 at FDA White Oak Campus to discuss bulk drug substances nominated for inclusion on the Section 503A Bulks List. The confirmed ag |
| June 4, 2026 | Source | New source added: Merck press release: Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trialmerck.com/news/mercks-enlicitide-decanoate-an-investigatio… | — |
| Merck & Co., Inc. (MSD) |
| June 4, 2026 | Research | New research: Enlicitide Decanoate (Oral Macrocyclic Peptide PCSK9 Inhibitor) Reduced LDL-C 55.8% in Phase 3 CORALreef Lipids (Merck, AHA 2025)merck.com/news/mercks-enlicitide-decanoate-an-investigatio… | Enlicitide decanoate (MK-0616) |
| Investigational once-daily ORAL macrocyclic peptide PCSK9 inhibitor (Merck/MSD; MK-0616). Late-breaking Phase 3 CORALreef Lipids results presented at AHA Scientific Sessions 2025 (announced 8 Nov 2025): in adults with or at risk for atherosclerotic cardiovascular disease on backg |
| June 3, 2026 | Source | New source added: Think twice before injecting peptides bought online: unauthorized products can seriously harm you (Public advisory RA-81874)recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-b… | — |
| Health Canada / Government of Canada |
| June 3, 2026 | Research | New research: Health Canada Public Advisory (RA-81874): Unauthorized Injectable Peptide Drugs Sold Online May Cause Serious Harmrecalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-b… | BPC-157, TB-500, Retatrutide, CJC-1295, DSIP, Epitalon, GHK-Cu, Ipamorelin, KPV, Melanotan I/II, MOTS-C, NAD+, SS-31, HCG |
| Health Canada public advisory (RA-81874, published 2026-04-09) warning consumers about serious health risks of unauthorized injectable peptide drugs sold online and marketed for anti-aging, weight loss, bodybuilding, athletic performance, injury recovery, sleep, mental focus, or |
| June 3, 2026 | Source | New source added: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in micenature.com/articles/s41586-026-10427-5 | — |
| Nature (Springer Nature) |
| June 3, 2026 | Research | New research: Unimolecular Quintuple Agonist GLP-1–GIP–Lanifibranor Corrects Obesity and Diabetes in Mice (Nature, 2026)nature.com/articles/s41586-026-10427-5 | GLP-1–GIP–lanifibranor, Semaglutide, Tirzepatide |
| Peer-reviewed preclinical study (Nature, published 29 April 2026; DOI 10.1038/s41586-026-10427-5; Helmholtz Munich with Indiana Biosciences Research Institute and the Novo Nordisk Research Center Indianapolis). Reports a unimolecular quintuple agonist, GLP-1–GIP–lanifibranor, a p |
| June 1, 2026 | Peptide | New peptide added: Bulevirtide | Bulevirtide |
| First/only FDA-approved treatment for chronic hepatitis delta virus (HDV). FDA accelerated approval May 22, 2026. Brand: Hepcludex (Gilead). |
| May 29, 2026 | Peptide | New peptide added: Pegzilarginase-nbln | Pegzilarginase-nbln |
| PEGylated recombinant arginase enzyme for Arginase 1 Deficiency. FDA approved February 23, 2026. |
| May 29, 2026 | Peptide | New peptide added: Navepegritide | Navepegritide |
| PEGylated CNP analog for achondroplasia. FDA approved February 27, 2026. |
| May 29, 2026 | Peptide | New peptide added: Icotrokinra | Icotrokinra |
| Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis. |
| May 28, 2026 | FDA approval | New FDA-approved peptide: Metreleptinaccessdata.fda.gov/drugsatfda_docs/label/2014/125390s000lbl.pdf | Metreleptin |
| Myalept — Leptin deficiency in generalized lipodystrophy |
| May 28, 2026 | Peptide | New peptide added: NMN (Nicotinamide Mononucleotide) | NMN (Nicotinamide Mononucleotide) |
| NAD+ direct precursor nucleotide; key longevity compound. |
| May 23, 2026 | Source | New source added: Self-reported side effects of semaglutide and tirzepatide in online communitiesnature.com/articles/s44360-026-00108-y | — |
| Nature Health (Springer Nature) |
| May 23, 2026 | Research | New research: Self-Reported Side Effects of Semaglutide and Tirzepatide in Online Communities (Nature Health, 2026)nature.com/articles/s44360-026-00108-y | Semaglutide, Tirzepatide |
| Peer-reviewed pharmacovigilance study (Nature Health, 2026; DOI 10.1038/s44360-026-00108-y) applying large-scale natural-language analysis to 410,198 Reddit posts (May 2019-June 2025) mentioning semaglutide or tirzepatide. Of 67,008 users who self-reported use, 43.5% described at |
| May 22, 2026 | Source | New source added: FDA Grants Accelerated Approval to Gilead's Hepcludex (bulevirtide-gmod), First and Only Approved Treatment for Chronic HDVgilead.com/news/news-details/2026/fda-grants-accelerated-ap… | — |
| Gilead Sciences, Inc. |
| May 22, 2026 | Source | New source added: FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infectionfda.gov/news-events/press-announcements/fda-approves-fir… | — |
| U.S. Food and Drug Administration |
| May 22, 2026 | Research | New research: FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV): Hepcludex (Bulevirtide-gmod)fda.gov/news-events/press-announcements/fda-approves-fir… | Bulevirtide |
| On May 22, 2026 the FDA granted accelerated approval to Hepcludex (bulevirtide-gmod), the first and only approved US treatment for chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. Bulevirtide is an HBV/HDV entry inhibitor (N |
| May 22, 2026 | FDA approval | New FDA-approved peptide: Bulevirtidefda.gov/news-events/press-announcements/fda-approves-fir… | Bulevirtide |
| Hepcludex — Chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. Granted accelerated approval based on reduction in HDV RNA and ALT normalization (Phase 3 MYR301, Week 48); clinical-outcome benefit not yet established and contin |
| May 21, 2026 | Source | New source added: Lilly TRIUMPH-1 Phase 3 Press Release: Retatrutide Pivotal Obesity Trialinvestor.lilly.com/news-releases/news-release-details/lillys-triple… | — |
| Eli Lilly and Company (investor.lilly.com) |
| May 21, 2026 | Source | New source added: Lilly TRIUMPH-1 Phase 3: Retatrutide 25% weight loss pivotal obesity trial May 2026prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-… | — |
| Eli Lilly and Company / PRNewsWire |
| May 21, 2026 | Research | New research: Retatrutide TRIUMPH-1 Phase 3: 28.3% Weight Loss at 80 Weeks (Eli Lilly, May 2026)investor.lilly.com/news-releases/news-release-details/lillys-triple… | Retatrutide, Tirzepatide, CagriSema |
| Phase 3 TRIUMPH-1 (Eli Lilly press release May 21, 2026): Retatrutide 12 mg produced 28.3% body weight loss (70.3 lb) over 80 weeks in adults with obesity without T2D. 9 mg: 25.9% (64.4 lb). 4 mg: 19.0% (47.2 lb). All doses met primary and key secondary endpoints. 45.3% of 12 mg |
| May 19, 2026 | Source | New source added: Safety Risks in the GLP-1 Market: An Update on Weight Loss Medication, May 2026safemedicines.org/2026/05/glp-1-safety-risks-may-2026.html | — |
| Partnership for Safe Medicines |
| May 19, 2026 | Research | New research: Safety Risks in the GLP-1 Market: May 2026 Update on Compounded & Counterfeit Semaglutide/Tirzepatidesafemedicines.org/2026/05/glp-1-safety-risks-may-2026.html | Semaglutide, Tirzepatide, Retatrutide |
| Partnership for Safe Medicines May 2026 roundup documenting safety risks across the GLP-1 weight-loss market: counterfeit Ozempic/Mounjaro seizures (US, Canada, Australia, India, UK), illicit online sales of unregistered semaglutide, tirzepatide and "research-use-only" retatrutid |
| May 18, 2026 | Source | New source added: FDA Warning Letter to 503B Facility Compounding Tirzepatide Post-Shortagesafemedicines.org/2026/05/may-18-2026.html | — |
| Partnership for Safe Medicines |
| May 18, 2026 | Research | New research: FDA Warns 503B Outsourcing Facility for Compounding Tirzepatide After Shortage Endedsafemedicines.org/2026/05/may-18-2026.html | Tirzepatide |
| FDA issued a warning to a 503B compounding pharmacy for producing tirzepatide after the official shortage ended, consistent with the agency's April 30, 2026 proposal to exclude GLP-1 drugs from the 503B bulks list. |
| May 4, 2026 | Source | New source added: FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugsorrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-o… | — |
| Orrick, Herrington & Sutcliffe LLP |
| May 1, 2026 | Source | New source added: Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (doc 2026-08552)federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-dru… | — |
| U.S. Government Publishing Office / FDA |
| April 30, 2026 | Source | New source added: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks Listfda.gov/news-events/press-announcements/fda-proposes-exc… | — |
| U.S. Food and Drug Administration |
| April 30, 2026 | Research | New research: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks Listfda.gov/news-events/press-announcements/fda-proposes-exc… | Semaglutide, Tirzepatide, Liraglutide |
| FDA proposed (Apr 30, 2026; Federal Register May 1, 2026) to leave semaglutide, tirzepatide, and liraglutide OFF the 503B Bulk Drug Substances List, finding no clinical need for outsourcing-facility bulk compounding now that shortages have ended. Comment period closes June 29, 20 |
| April 22, 2026 | Source | New source added: FDA Pharmacy Compounding Advisory Committee Meeting July 23-24, 2026fda.gov/advisory-committees/advisory-committee-calendar/… | — |
| U.S. Food and Drug Administration |
| April 16, 2026 | Source | New source added: FDA's Pep(tide) Rally! What Compounders and Industry Need to Knowthefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-… | — |
| The FDA Law Blog |
| April 16, 2026 | Source | New source added: FDA Moves Toward Easing Restrictions on Certain Peptidesfiercepharma.com/pharma/fda-advisory-committee-set-weigh-taking-a… | — |
| Fierce Pharma |
| April 16, 2026 | Source | New source added: FDA to Remove 12 Popular Peptides from the Category 2 "Do Not Compound" Listfrierlevitt.com/articles/fda-peptides-do-not-compound-list-updat… | — |
| Frier Levitt — FDA Healthcare Law |
| April 16, 2026 | Source | New source added: FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances Listorrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-… | — |
| Orrick, Herrington & Sutcliffe LLP |
| April 16, 2026 | Research | New research: FDA Announces Removal of 12 Peptides from Category 2 — April 15, 2026orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-… | BPC-157, TB-500, Semax, Epitalon, DSIP, GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-C, LL-37, DiHexa |
| On April 15, 2026, FDA announced removal of 12 peptide bulk drug substances from Category 2 effective April 22, 2026, following withdrawal of nominations. No longer "significant safety risk" designation but not yet on 503A Bulks List. PCAC reviews July 23-24, 2026. |
| April 15, 2026 | Source | New source added: FDA Announces Change in Status of 12 Peptidesssrpinstitute.org/news/fda-announces-change-in-status-of-12-peptid… | — |
| SSRP Institute (Seeds Scientific Research & Performance) |
| April 15, 2026 | Source | New source added: FDA Federal Register Notice — Removal of 12 Peptides from Category 2 & PCAC Schedulingfda.gov/media/94155/download | — |
| U.S. Food and Drug Administration |
| April 1, 2026 | Research | New research: FDA Novel Drug Approval: Foundayo (Orforglipron) — First Oral GLP-1 Agonistfda.gov/drugs/novel-drug-approvals-fda/novel-drug-approv… | Orforglipron |
| FDA approved Foundayo (orforglipron) April 1, 2026. First oral GLP-1 receptor agonist for weight management in adults with obesity or overweight. Eli Lilly. |
| April 1, 2026 | FDA approval | New FDA-approved peptide: Orforglipron | Orforglipron |
| Foundayo — Obesity or overweight with at least one weight-related comorbidity in adults; combined with reduced-calorie diet and increased physical activity |
| March 19, 2026 | Source | New source added: Lilly TRANSCEND-T2D-1 Phase 3: Retatrutide HbA1c reduction in type 2 diabetes Mar 2026investor.lilly.com/news-releases/news-release-details/lillys-triple… | — |
| Eli Lilly and Company / PRNewsWire |
| March 17, 2026 | Research | New research: FDA Novel Drug Approval: Icotyde (Icotrokinra) — First Oral Peptide for Plaque Psoriasisfda.gov/drugs/novel-drug-approvals-fda/novel-drug-approv… | Icotrokinra |
| FDA approved Icotyde (icotrokinra) March 17, 2026. First-in-class oral macrocyclic peptide IL-23R antagonist for moderate-to-severe plaque psoriasis. J&J / Protagonist Therapeutics. |
| March 17, 2026 | FDA approval | New FDA-approved peptide: Icotrokinra | Icotrokinra |
| Icotyde — Moderate-to-severe plaque psoriasis in patients 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy |
| February 27, 2026 | Research | New research: FDA Novel Drug Approval: Yuviwel (Navepegritide) — CNP Analog for Achondroplasiafda.gov/drugs/novel-drug-approvals-fda/novel-drug-approv… | Navepegritide |
| FDA approved Yuviwel (navepegritide) Feb 27, 2026 for pediatric achondroplasia. PEGylated CNP analog activating NPR-B to promote bone growth. BioMarin. |
| February 27, 2026 | FDA approval | New FDA-approved peptide: Navepegritide | Navepegritide |
| Yuviwel — Increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses |
| February 23, 2026 | Research | New research: FDA Novel Drug Approval: Loargys (Pegzilarginase-nbln) — Enzyme for Arginase 1 Deficiencyfda.gov/drugs/novel-drug-approvals-fda/novel-drug-approv… | Pegzilarginase-nbln |
| FDA approved Loargys (pegzilarginase-nbln) Feb 23, 2026. PEGylated arginase enzyme for Arginase 1 Deficiency. IV infusion with dietary protein restriction. |
| February 23, 2026 | FDA approval | New FDA-approved peptide: Pegzilarginase-nbln | Pegzilarginase-nbln |
| Loargys — Hyperarginemia in adults and pediatric patients 2 years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction |
| January 1, 2026 | Source | New source added: FDA Novel Drug Approvals for 2026fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approv… | — |
| U.S. Food and Drug Administration — Center for Drug Evaluation and Research |
| December 11, 2025 | Source | New source added: Lilly TRIUMPH-4 Phase 3: Retatrutide 28.7% weight loss + knee osteoarthritis Dec 2025investor.lilly.com/news-releases/news-release-details/lillys-triple… | — |
| Eli Lilly and Company / PRNewsWire |
| October 7, 2025 | Peptide | New peptide added: TB-500 | TB-500 |
| Connective tissue repair |
| October 7, 2025 | Peptide | New peptide added: BPC-157 | BPC-157 |
| Bone and cartilage healing |
| October 7, 2025 | Peptide | New peptide added: GHK-Cu | GHK-Cu |
| Bone remodeling support |
| October 7, 2025 | Peptide | New peptide added: Collagen Peptides | Collagen Peptides |
| Structural bone and joint support |
| October 7, 2025 | Peptide | New peptide added: Calcitonin | Calcitonin |
| FDA-approved bone resorption inhibitor |
| October 7, 2025 | Peptide | New peptide added: Pentosan Polysulfate | Pentosan Polysulfate |
| Cartilage and joint protection |
| October 7, 2025 | Peptide | New peptide added: Abaloparatide | Abaloparatide |
| Advanced bone anabolic |
| October 7, 2025 | Peptide | New peptide added: Teriparatide | Teriparatide |
| FDA-approved bone builder |
| October 7, 2025 | Peptide | New peptide added: Melanotan II | Melanotan II |
| Melanocortin system activator |
| October 7, 2025 | Peptide | New peptide added: Prostatilen | Prostatilen |
| Prostate and male hormone support |
| October 7, 2025 | Peptide | New peptide added: Thyreogen | Thyreogen |
| Thyroid function support |
| October 7, 2025 | Peptide | New peptide added: DHEA Peptide | DHEA Peptide |
| Hormone precursor support |
| October 7, 2025 | Peptide | New peptide added: Oxytocin | Oxytocin |
| Bonding and relaxation hormone |
| October 7, 2025 | Peptide | New peptide added: PT-141 | PT-141 |
| Sexual function peptide |